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CHAFER 1 
GENERAL INTRODUCTION 
General properties of phosphorylase kinase 
Protein kinases are defined as the enzymes catalyzing 
the transfer of the 7-phosphate of MgATP to an acceptor 
amino acid in a protein substrate. The reaction catalyzed 
by protein kinases is called phosphorylation. The protein 
kinases differ in substrate specificity, subunit 
composition, activation mechanism, but all the eukaryotic 
protein kinases are found to share sequence similarities 
throughout a conserved catalytic core (1). The protein 
kinases are a large family of enzymes, and phosphorylase 
kinase (PhK) is one of them. 
PhK has a subunit composition of (aPyô)^ and a 
molecular weight of 1.3x10® kDa (2) . There are two major 
pathways for the regulation of glycogenolysis involving 
PhK. The first pathway is hormonal stimulation of 
glycogenolysis (3-5). In the presence of epinephrine or 
glucagon, an increased cyclic AMP triggers the activation 
of cyclic AMP-dependent protein kinase (cAPK), which 
activates PhK by phosphorylation on the of and j8 subunit. 
The activated PhK catalyzes the phosphorylation of glycogen 
phosphorylase b, the inactive form, and converts it into 
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the active a form which catalyzes the breakdown of glycogen 
to glucose-l-phosphate. 
The other cascade is involved in the neural and cx-
adrenergic hormonal control of glycogenolysis. These 
control systems are mediated by Ca^* which serves a 
mediator to link glycogenolysis to muscle contraction (6-
9). In the resting state of skeletal muscle, the Ca^* 
concentration in the cytosol is less than 10'® M. Muscle 
contraction is triggered by the release of Ca^* (10'® to 10'® 
M) from sarcoplasmic reticulum. Because PhK is highly 
sensitive to Ca^* concentrations and muscle contraction is 
also a Ca^* dependent manner, PhK is thought to coordinate 
the muscle contraction with glycogenolysis. There are two 
modes of PhK activation by Ca^*. First, Ca^* binds to 6 
subunit (calmodulin) of PhK and stimulates its Ca^* 
dependent activity. Second, exogenous calmodulin binds to 
the calmodulin binding sites on a and 0 subunits in a Ca^* 
dependent manner, which stimulates PhK activity. 
PhK recently has been shown to be a dual specificity 
kinase (10) . The specificity of PhK is dependent on the 
metal ions; Mg^* activates seryl phosphorylation of 
phosphorylase Jb and Mn^* causes tyrosyl phosphorylation of 
angiotensin II. In addition to the known glycogenolysis 
cascade, new substrate(s) and pathway(s) might exist for 
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PhK to reflect its tyrosine kinase activity. 
PhK is a very large enzyme and its regulation is very 
complicated (11, 12). In addition to multi-site 
phosphorylation, pH, ADP, glycogen, calmodulin, and metal 
ions, such as Ca^*, Mg^*, Mn^*, affect its activity. PhK 
activity was shown to be activated by Mg^*. Its activity 
was activated by Mn^* (MnATP) and then inhibited by 
increasing Mn^* (or free Mn^*) (13) . The location of the 
metal ion binding sites in y will be described in PAPER 3. 
A lower kinase activity at pH 6.8 than at 8.2 was found in 
nonactivated PhK (the activity ratio (pH 6.8/pH 8.2) is 
0.04) . The pH dependency is changed as the holoenzyme 
undergoes phosphorylation, proteolysis, or dissociation 
into ccyô and 7Ô complexes (14) . For example, the ratio of 
activity at pH 6.8/pH 8.2 ranges 0.3-1 for PhK which is 
phosphorylated by cAPK or by autophosphorylation, 
respectively. It has been suggested that there are two ADP 
binding sites per a(3yô tetramer. ADP is known to be an 
allosteric activator of nonactivated PhK. The allosteric 
site for activation is in the /3 subunit (15) . ADP is also 
the product of the kinase reaction and has been shown to be 
a competitive inhibitor of 7 subunit activity (see later in 
kinetic mechanism of recombinant 71.300) • This ADP binding 
site is believed to be in the active site of the 7 subunit 
(16) 
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Roles of subunits 
Two isozymes of PhK have been identified and isolated 
from white (fast-twitch) and red (slow-twitch) muscles. 
The difference is due to the largest subunits, designated a 
and a' (17, 18). The rabbit white skeletal muscle PhK 
composed of four different subunits with a stoichiometry of 
(a/Syô)^ (19) . The molecular weights for a, 13, y, and Ô 
subunits are 138,422 (20), 125,205 (21), 44,673 (22), and 
16,680 (23), respectively. 
The Ô subunit is calmodulin, a calcium binding 
protein, and confers calcium sensitivity upon PhK (24). 
The ô subunit differs from bovine brain calmodulin in only 
two amino acids and has the ability to activate calmodulin-
dependent enzymes (25). Calmodulin acts as a Ca^*-
dependent mediator to control a variety of enzymes 
responding to physiological fluxes of Ca^*. It has been 
suggested that PhK requires Ca^* for its activity (7) and 
the binding of Ca^* is through the ô subunit (26, 27). 
The 7 subunit was shown to contain a catalytic site 
(28-33) . One of the early experiments was to use lithium 
bromide to promote the dissociation of PhK. Two partial 
complexes, Û17Ô and yô, obtained by Chan and Graves, both of 
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which retained the catalytic activity of PhK, indicating 
the catalytic site is in the yô complex but not in the a 
and j8 subunit (29, 30) . Later, the isolation of active y 
subunit alone further demonstrated that the y subunit is 
the catalytic subunit (16, 32). The y subunit is composed 
of 386 amino acids (15). The catalytic domain is located 
at the N-terminus (-y^.g^g) and is homologous with the 
catalytic domains of other protein kinases (1). In 
comparison with cAPK, a 36% sequence identity within the 
catalytic core of protein kinases was found. Several 
catalytic properties of 7 subunit and cAPK were compared in 
this dissertation even though these two enzymes display 
several other differences including substrate specificities 
and interactions with other subunits (34, 35). The C-
terminal region of y, Yasv-see/ is thought to be the 
calmodulin binding domain. Two calmodulin binding domains 
corresponding to 7302-326 (PhK 13) and 7342-366 (PhK 5) were 
identified by Dasgupta et al. (36). The possible function 
of the C-terminus region was studied in CHAPTER 4. 
Comparison of a and /? subunit sequences indicates that 
these two proteins are homologous (21). However, not much 
is known about their functional domains due to the 
difficulty of isolating the individual subunits in a native 
folded form. It has been showed that a/P subunits mixture 
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inhibited the activity of 7 subunit and ^-calmodulin 
complex (37). Proteolysis of PhK a and |8 subunit (5) , 
dissociation of PhK by lithium bromide (29), and 
phosphorylation by cAPK (19, 38) or Ca^''-dependent 
autophosphorylation (4, 39) can result in the activation of 
PhK. These results suggest that the role of a or 0, or 
perhaps both, is to suppress the activity of the y subunit. 
Different activation mechanisms of PhK could release the 
constraint of a and/or jS upon the 7 subunit. Recently, the 
isolation of the autoinhibitory peptide derived from /3 
subunit, which inhibits the 7 subunit activity, further 
demonstrates that j8 subunit serves a regulatory function 
(61) . 
The binding of Ca^*/calmodulin to the a and /S subunits 
can activate PhK. A number of possible calmodulin binding 
regions/peptides of PhK were determined by different 
approaches (36, 40-42). Together, there are four 
calmodulin binding regions on each a and /8 (42) and there 
are two regions, PhK 13 and PhK 5, in each 7 subunit (36). 
These calmodulin binding peptides can be grouped into two 
categories : the peptides derived from a subunit which 
exhibit low affinity and the peptides from (3 and 7 which 
have high affinity toward calmodulin. Some of these 
peptides and several other established calmodulin binding 
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peptides can inhibit activated PhK (41, 43). Several 
hypotheses have been proposed to explain the possible 
regulatory properties of these peptides (41, 43). Our 
studies suggest that the inhibition by some of these 
calmodulin binding peptides, e.g. PhK 13, binds directly to 
the 7 active site. It is suggested that the active site of 
y might have the similar structural to the calmodulin 
binding site (43). Detailed description of our studies 
will be in CHAPTER 4. 
Inclusion bodies and renatured recombinant proteins 
In recent years, many proteins have been cloned from 
various sources because of the accelerated development of 
molecular biology. Many examples of the soluble eucaryotic 
proteins expressed in E. coli are found in the cytoplasm in 
an insoluble aggregated form, called "inclusion bodies" 
(44, 45). The overexpressed protein is the major component 
in these inclusion bodies, which are associated with other 
cellular components. Despite the insolubility of the 
inclusion bodies, a significant purification can be 
achieved by cell breakage, differential centrifugation, and 
washing procedures (44-47). Recombinant proteins recovered 
from the inclusion bodies usually are not biologically 
active. It is difficult to convert these biologically 
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inactive, but relatively pure, inclusion bodies into the 
correctly folded and enzymatically active proteins with 
reasonable recovery. After solubilization of the inclusion 
body by a strong dénaturant (e.g. guanidine hydrochloride 
and urea), followed by specific renaturation conditions in 
which refolding occurs, one can obtain a biologically 
active and soluble protein (44, 45). However, the isolated 
soluble proteins could be the mixture of correctly folded 
(high activity form) and incorrectly folded (low activity 
form) recombinant proteins. This proved to be the case for 
the renatured recombinant PhK Y1.300 (35, 48). A 
chromatography step was used to remove the incorrectly 
folded recombinant proteins (35). 
Why does the renatured recombinant proteins have two 
different structural forms? In the case of Yi-aoo, both are 
the same as judged by SDS-PAGE (48), and there is only one 
coding sequence in the expression vector, suggesting that 
these two forms have the same polypeptide composition. In 
other words, the low-activity form is not derived from an 
incorrectly translated sequence. Our findings suggest that 
the renatured recombinant 71.300 might exist in two different 
conformational states in equilibrium, which have different 
catalytic efficiencies. The data lead us to propose that 
the low-activity form may be kinetically "trapped" to the 
9 
incorrectly folded (or partly folded) state. To obtain the 
authentic kinase activity of the renatured recombinant 
proteins, it is necessary to remove those incorrectly 
folded forms. 
Secondary structural analyses of mutant proteins 
Site-directed mutagenesis to generate mutant proteins 
is commonly used to probe the structure-function 
relationship. It is important to note that the loss of the 
enzymatic activity of a mutant protein could be because of 
several factors including the involvement of the mutated 
residues in chemical reaction, substrate binding, or 
conformational stability. It is required to demonstrate 
that the mutant proteins have similar folding structures 
compared to wild-type protein before further characterizing 
them. Therefore, it is desirable to have a rapid technique 
for characterizing the structure of mutant proteins. FT-
IR/PAS (Fourier transform infrared/ Photoacoustic 
spectroscopy) is one of such techniques which was used 
recently in our laboratory to evaluate the secondary 
structure of proteins (48). Even though we were unable to 
distinguish the a-helical and random coil structures 
satisfactorily, the conformation disruption caused by a 
single point mutation can be detected unambiguously by FT-
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IR/PAS (CHAPTER 3). We concluded that FT-IR/PAS may be one 
of the best choices to study the conformation of the 
recombinant protein and its mutant forms. Features of 
easiness, sensitivity, reliability, and rapidity to obtain 
high-quality spectra from very small amounts of protein 
make FT-IR/PAS an amenable technique to study protein 
conformation. 
Substrate specificity 
Based on the sequences flanking the phosphorylation 
site in phosphorylase b, Graves and his colleagues have 
defined the phosphorylation site specificity of PhK by 
extensive kinetic analyses of peptide substrates (49-52). 
As indicated in Figure 1, the sequence flanking the protein 
substrate phosphorylation site of PhK has two basic 
residues, and R^®, which are important specificity 
determinants for PhK. Therefore, I predict that some 
acidic side chains of the PhK participate in the 
recognition of the basic residues in the peptide substrate. 
The interactions between the enzymes and their 
substrates can be identified by analyzing the crystal 
structures of the enzymes bound to their substrates. No 
crystal structure is available for y but molecular modeling 
suggests that its structure is considerably similar to that 
Figure 1. Substrate and pseudosubstrate peptides for PhK 
and cAPK. The substrate and pseudosubstrate 
peptides for both PhK and cAPK are aligned 
based on the substrate phosphorylation site 
(designated p site). Each residue is assigned 
a position relative to the p site. Basic 
residues involved in peptide recognition are 
underlined. The acidic residues from cAPK and 
y thought to interact with those basic 
residues are indicated. 
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gl27 
gl70/g230 
PKI [5-24] TTYADFIASGRTGRRNAIHD 
P-6 P-3 P 
9-18 peptide KRKQISVRGL 
glS4 ^ip222 
illl 
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of cAPK. The crystal structure of the cAPK with a bound 
inhibitor peptide, PKI [5-24], has been solved (53, 54). 
The R^®RNA^^I sequence in PKI is referred to as the 
consensus sequence with A^^ replacing the phosphorylation 
site (P site) (Figure 1) . and will be referred to 
as P-3 and P-2 sites, respectively. The overall 
architecture of the crystal structure is its bilobal shape 
containing a deep cleft between the two lobes, small lobe 
and large lobe. The small lobe corresponds to the N-
terminus of the catalytic core and the large lobe is mainly 
associated with the C-terminal portion of the protein. The 
inhibitor peptide binds in an extended conformation in a 
cleft between the two lobes. However, the consensus 
sequence of PKI, R^®RNAI, binds primarily in the large 
lobe. There are four acidic residues which are important 
for the binding of PKI, including and interact with 
R^' at the P-2 site, E""' contributes to the binding of R^® 
at the P-3 position, and E^" points to R^^ at the P-6 
position (Figure 1) (53, 54). 
In 7, there are two acidic residues (E^^^ and E"^) 
corresponding to E"' and E^'" in cAPK, respectively (1) . 
However, and E^°^ in cAPK are replaced by T^^^ and 
respectively (Figure 1). It is not surprising that 
differences exist in the sequence alignment of the residues 
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between the two proteins because PhK only phosphorylates 
in phosphorylase b and pho sphory 1 a s e b can not be 
phosphorylated by cAPK. Instead, cAPK phosphorylates a 
wide range of exogenous proteins. Some aspects of the 
specificity of phosphorylation are different between PhK 
and cAPK but what exactly causes these differences remains 
to be established. 
Localization of substrate and metal ion binding sites by 
scanning mutations 
In the tertiary structure of an enzyme, the charged 
amino acids are likely to occupy the exposed positions and 
to make major contributions to the recognition of charged 
residues or ligands (55-57). By using charged to alanine 
scanning mutagenesis, Gibbs and Zoller (58, 59) have 
identified three glutamic residues in yeast cAPK that are 
involved in recognition of the peptide substrate Kemptide. 
These three glutamic residues in yeast cAPK are equivalent 
to E 127, 170 and 230 in mammalian cAPK. Their results 
were in agreement with the data from the crystal structure 
of an inhibitor peptide bound to the cAPK (53, 54). 
Similar approaches, charged to alanine and charge reversal 
mutations, were applied in my study to probe the ionic 
interactions between PhK and peptide substrate. The acidic 
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residues in 7 were the targets for mutageneses. However, 
there are many negative charged residues in 7. Therefore, 
I used the following approaches to reduce the number of 
mutations (Table 1) . (a) I used the truncated 71.300 instead 
of full-length 7 since both of them have the same K„ values 
for both substrates, phosphorylase b and ATP. (b) I only 
mutated the sequence between subdomain V and XI 
(corresponding to large lobe in cAPK crystal structure) 
because these regions have been implicated for peptide 
substrate binding (53, 54). (c) I changed the acidic 
residues to alanine in groups of 1, 2, or 3 to further 
reduce the number of mutations. (d) The invariant acidic 
residues were not mutated because those residues should 
have the universal function and not be involved in 
substrate recognition. (e) and were also replaced 
with positive charged residues because these two positions 
were involved in peptide substrate binding in cAPK (53, 54, 
58, 59). Further studies on these two positions seemed to 
be necessary. 
All the mutants (truncated 7  forms, 71.300) were 
screened for kinase activity in vitro using either 
phosphorylase b (Figure 2) or 9-18 peptide (Figure 3) as a 
substrate. Those mutants with reduced specific activities 
were subjected to detailed kinetic analyses with 
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Table 1. Location of charged to alanine and charge 
reversal mutants of 71-300 • 
Mutants Y sequence kinase subdomain 
VFDLMKKGELFDYLTEKVT V 
1 A 
2 K 
3 A 
4 A 
LSEKETRKIMRALLEV VI 
5 A A 
6 A 
RDLKPENILLDDDM VII 
7 A 
8 R 
9 A 
10 A 
11 A 
CQLDPGEKLREVC VII & VIII 
12 A 
13 A A 
IIECSMNDNHP6YGKEV VIII 
14 A A 
15 A 
SPEWDDYSDTVKDLV X & XI 
16 A AA 
17 A A 
Figure 2. The serine kinase specific activity of wild-type Y1.300 was determined in 
the presence of 50 mM Tris (pH 8.2), 50 mM Hepes, 5 tnM DTT, 10 mM 
MgClj, 10 mg/mL phosphorylase b, and 1 mM [-y-^^P]ATP. The wild-type 
specific activity (3.5 /imol ^^P/min/nmol enz) was used as 100%. 
Specific Activity (%) 
81 
Figure 3 . The serine kinase specific activity of wild-type 71.300 was determined in 
the presence of 50 mM Tris (pH 8.2), 50 mM Hepes, 5 mM DTT, 10 mM 
MgClj, 10 mg/mL mM MgClj, 4 mM 9-18 peptide, and 1 mM [y-^^P]ATP. The 
wild-type specific activity (1.4 jumol ^^P/min/nmol enz) was used as 
100%. 
Specific Activity (%) 
o z  
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phosphorylase b or 9-18 peptide. Two mutants, ElllK and 
E154R, having unique properties with respect to 
phosphorylase b (and peptide substrate) were further 
analyzed and described in CHAPTER 3 and CHAPTER 4. 
All 17 mutants were also used to explore the metal ion 
binding site of Yiooo- It has been shown that free Mn^* 
inhibits 71.300 its serine kinase activity. If one of the 
negative charged residues in Y1.300 participates in chelating 
cation ions, I hoped that mutation might change the 
inhibition pattern by Mn^*. Two mutants, ElllK and E154R, 
had a different response to Mn^* compared to wild-type "yi-300 
(Figure 4). As shown in Figure 4, the inhibition of both 
mutants by free Mn^* was no longer observed at 1.5 mM ATP 
and 3.5 mM Mn^*. These two mutants were further 
characterized and described in CHAPTER 3. 
Kinetic mechanism of recombinant 71.300 
PhK was shown earlier to use a random bi bi kinetic 
mechanism (50) but studies with Yi.jgg-calmodulin complex 
suggest a random (60) or ordered mechanism (61). I have 
expressed and purified the recombinant 71.300; its kinetic 
mechanism of this enzyme form was evaluated. Because 
competitive inhibitors of substrates can be used to 
differentiate between random and ordered mechanisms (62), 
Figure 4. Effect of on wild-Type Y1.300 and its mutant forms. Each 
recombinant protein was assayed at 10 mg/mL phosphorylase b, 50 mM Tris 
(pH 8.2), 50 mM Hepes, 5 mM DTT, 1.5 mM [-y-^^P]ATP, and 3.5 mM MnClj or 
1.5 mM MnClj. The % specific activity of each recombinant protein is 
given as the ratios of the specific activity obtained at 3.5 mM MnClj 
to the specific activity obtained at 1.5 mM MnClg. 
Specific Activity (%) 
EZ 
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the kinetic mechanism of recombinant 71.300 using the 
inhibitors, PhK 13 and ADP, was examined. PhK 13 will be 
shown later in CHAPTER 4 to act as a competitive inhibitor 
for phosphorylase b and a noncompetitive inhibitor for ATP. 
ADP is a competitive inhibitor to ATP with Kis=50.4 ± 6.1 
/iM and a noncompetitive inhibitor to phosphorylase b 
(Kis=188 ± 14 iiM and Kii=189 ± 14 jiM) . The data suggest 
that recombinant Y1.300 also has the random bi bi mechanism. 
Specific aims 
Protein kinases play an important role in the 
regulation of many cellular processes by phosphory1ating 
their target proteins on serine, threonine, or tyrosine 
residues. The overall aim is to elucidate the substrate 
specificity and regulation of PhK. These studies will 
provide a foundation for better understanding of how PhK 
works. 
PhK and recombinant 71.300 can phosphorylate seryl and 
tyrosyl residues dependent on the metal ions. One 
objective was to understand how 71.300 recognizes specific 
hydroxyl groups in the substrates. What structural 
features of the 71.300 subunit are important for binding of 
the substrates in the catalytic reaction? How do the metal 
ions influence the substrate specificity? Where are the 
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metal ion binding sites? Furthermore, a catalytic 
fragment, 71.299/ without the C-terminal calmodulin binding 
domains was found to be constitutively active (63). What 
are reasons which might cause the activation? Is it 
possible that an autoinhibitory domain(s) exists in the C-
terminus of 7 subunit (64)? If there is an autoinhibitory 
domain(s), what is the inhibition mechanism(s) and where is 
it. Recombinant 71.300 and its mutant forms were used to 
address these questions. 
Dissertation organization 
The first chapter is a general introduction of this 
dissertation. CHAPTER 2, which has been published in 
Molecular and Cellular Biochemistry, deals with the 
expression, purification, characterization, and deletion 
mutations of phosphorylase kinase 7 subunit. In this 
study, we establish that 71.300 can be used as a model enzyme 
to study substrate specificity, regulation, and metal ion 
binding sites. We also propose the existence of an 
a u t o i n h i b i t o r y  d o m a i n ( s )  i n  t h e  C - t e r m i n u s  o f  7 .  
CHAPTER 3, which has been submitted to Biochemistry 
for publication and is in the revised form, discusses the 
identification of the substrate and metal ion binding sites 
in 71.300 - CHAPTER 4, which will be submitted to The Journal 
26 
of Biological Chemistry for publication, describes the 
identification of the pseudosubstrate binding domain in the 
C-terminus of y. In this paper, we also describe the 
mapping of the substrate binding site of 71.300 • 
A general summary and discussion of the entire 
dissertation and an outlook for further work are also 
offered. References cited in the GENERAL INTRODUCTION and 
the GENERAL SUMMARY AND DISCUSSION follow the GENERAL 
SUMMARY AND DISCUSSION. 
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CHAPTER 2 
EXPRESSION, PURIFICATION, CHARACTERIZATION, AND DELETION 
MUTATIONS OF PHOSPHORYLASE KINASE 7 SUBUNIT; IDENTIFICATION 
OF AN INHIBITORY DOMAIN IN THE 7 SUBUNIT 
A paper published in Molecular and Cellular Biochemistry 
127/128, 7-18 (1993). 
Chi-Ying F. Huang^, Chiun-Jye Yuan^, Nataliya B. Livanova^, 
and Donald J. Graves^' ^ 
^Department of Biochemistry and Biophysics, Iowa State 
University, Ames, Iowa 50011. 
^A. N. Bach Institute of Biochemistry, Academy of Science, 
Moscow 117071, Russia 
^To whom requests for reprints should be addressed. The 
phone number is 515-294-8961 and the Fax number is 515-294-
0453 . 
This work was supported by Research Grant GM-09587 from the 
National Institutes of Health, United States Public Health 
Service. This is Journal Paper No. J-15289 of the Iowa 
Agriculture and Home Economics Experiment Station, Ames, 
Iowa, Project 2120. 
28 
ABSTRACT 
A catalytic fragment, 71-290/ derived from limited 
chymotryptic digestion of phosphorylase b kinase (Harris, 
W. R. et al., [1990] J. Biol. Chem., 265, 11740-11745), is 
reported to have about six-fold greater specific activity 
than does the 7 subunit-calmodulin complex. To test 
whether there is an inhibitory domain located outside the 
catalytic core of the y subunit, full-length wild-type and 
seven truncated forms of 7 were expressed in E. coli. 
Recombinant proteins accumulate in the inclusion bodies and 
can be isolated, solubilized, renatured, and purified 
further by ammonium sulfate precipitation and Q-Sepharose 
column. Four out of seven truncated mutants show similar 
(71.353 and 7i.34i) or less (71-331 and 71.275) specific activity 
than does the full-length wild-type 7, 71.386- Three 
truncated forms, 71.316, 71.300/ and 71.290 have molar specific 
activities approximately twice as great as those of the 
full-length wild-type 7 and the nonactivated holoenzyme. 
All recombinant 7s exhibit similar values for both 
substrates, i.e., about 18 /zM for phosphorylase b and about 
75 /zM for MgATP. Three truncated 7 s ,  7 1 . 3 1 6 /  7 i-3oo/ and 7 1 . 2 9 0 /  
have a 1.9- to 2.5-fold greater catalytic efficiency 
(%nax/^) than that of the full-length wild-type 7 and a 
3.5- to 4.5-fold greater efficiency than that of the 
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truncated ^1-331 • This evidence suggests that there is at 
least one inhibitory domain in the C-terminal region of y, 
which is located at 7301-331- 7i-29o/ but not T1.276/ which 
contains the highly conserved kinase domain, is the minimum 
sequence required for the 7 subunit to exhibit 
phosphotransferase activity. Both 71.290 and 71.300 have 
several properties similar to full-length wild-type 7, 
including metal ion responses (activation by free Mg^* and 
inhibition by free Mn^*) , pH dependency, and substrate 
specificities. 
(Key Words: Phosphorylase kinase 7 subunit, inhibitory 
domain) 
INTRODUCTION 
In 1955, Fischer and Krebs reported that the 
conversion of phosphorylase Jb to a could occur in rabbit 
muscle extracts in the presence of ATP and divalent 
cations, including Ca^* (1). In the next year the 
researchers reported that this conversion was due to the 
phosphorylation of phosphorylase b caused by the 
phosphorylase Jb to a converting enzyme (2), later named 
phosphorylase b kinase (PhK). This discovery has greatly 
influenced the understanding of cellular regulatory 
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mechanisms. 
Although much is known about PhK (3, 4), it still is 
unclear precisely how Ca^* activates this enzyme. PhK has 
a mass of 13 00 kDa and a subunit composition in white 
skeletal muscle of (a,/3,7,0)4. The 7 subunit is 
catalytically active, and its N-terminal region shares 
sequence homology with the catalytic domains of other 
protein kinases (7) . The regulatory subunits, a and /8, 
inhibit the 7 subunit (5, 8). This inhibition is released 
by phosphorylation of the a and S subunits by the cAMP-
dependent protein kinase (cAPK). The Ô subunit is 
calmodulin and confers Ca^* sensitivity upon the enzyme. 
The C-terminal region of 7302-366 is thought to encompass the 
calmodulin binding domains (9). Exogenous calmodulin is 
known to stimulate the 7 subunit isolated from rabbit 
skeletal muscle (5, 14) and recombinant forms (11, 16, 17, 
20) . Yet, the relation between calmodulin binding and 
reactivation is unclear. Several attempts (14, 27) have 
been made to isolate free 7 subunit from rabbit skeletal 
muscle. Only small amounts of biologically active 7 can be 
obtained. 7 subunit (full-length or truncated forms) and 
an isoform of 7 have been expressed in E. coli (11, 12, 13, 
20) and in mammalian cell lines (16, 17). In most 
instances, the recombinant 7 is biologically inactive (11, 
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12, 13, 20). Reactivation of y can be achieved partly by 
renaturation. Low activity level occurs in the soluble 
form, but purification of this form is difficult (16, 17). 
The inhibitory domain concept was proposed by Corbin 
et al. (6). There are three features of the inhibitory 
domain (or pseudosubstrate sequence) in protein kinases: 
(1) the domain is located outside the catalytic domain; (2) 
the domain is responsible for maintaining the enzyme in the 
inactive form by mimicking a substrate; (3) the domain's 
removal generates active proteins (30, 31). Several 
protein kinases, e.g., myosin light chain kinase and 
protein kinase C, have been shown to contain an inhibitory 
domain or a pseudosubstrate sequence in their primary 
structures (30, 31). Recently, Harris et al. described a 
catalytic fragment, 71.298/ derived from limited chymotryptic 
digestion of PhK, which exhibited specific activity about 
12-fold greater than that of 7 and about 6-fold greater 
than that of 7 subunit-calmodulin complex (10) . But, the 
reason for kinase activity activation remains elusive. One 
of our hypotheses is that in the C-terminal region an 
inhibitory domain may exist that overlaps the calmodulin 
binding region. Release of inhibition can occur by removal 
of this inhibitory domain, which subsequently causes 
activation (30, 31). A similar idea has been suggested by 
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Kemp and Pearson, who proposed a pseudosubstrate binding 
site located at the C-terminus of the y subunit, 7332.353 
(30). To explore the possible existence of an inhibitory 
domain in the C-terminus of 7 and to study the catalytic 
properties of the PhK 7 subunit with or without the 
calmodulin binding domain, we used oligonucleotide-directed 
mutagenesis to construct full-length wild-type 7 and seven 
d e l e t i o n  m u t a t i o n s  i n  t h e  C - t e r m i n a l  d o m a i n  o f  t h e  7  
subunit. In this paper, we describe processes to obtain the 
biologically active recombinant 7 (full-length wild-type 
and truncated forms) and report some characteristics of 
these recombinant proteins. 
MATERIALS AND METHODS 
Materials. Restriction enzymes were purchased from 
New England Biolabs or Promega. Q-Sepharose was obtained 
from Pharmacia, and dithiothreitol (DTT) from Pierce. [ 7 -
^^P]ATP was purchased from ICN Biomedicals. The other 
reagents were purchased from Sigma. PhK and phosphorylase 
b were prepared from rabbit skeletal muscle, as described 
in (33, 34, 43). The 9-18 peptide substrate(Lys-Arg-Lys-
Gln-Ile-Ser-Val-Arg-Gly-Leu), corresponding to the amino 
terminal residues 9-18 of phosphorylase b, was synthesized 
at Iowa State University protein facility and purified by 
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reverse phase HPLC C-18 column. 
SDS-Polyacrylamide Gel Electrophoresis (SDS-PA6E). 
SDS-PAGE was carried out in 10% acrylamide gel, as 
described (26). A Zeineh scanning densitometer from LKB 
Instruments was used to scan the dried gel under a tungsten 
lamp. 
Protein Concentrations Determination. Concentrations 
were determined by the Bradford assay, which used 
commercially prepared reagents from Bio-Rad (25). 
Phosphorylase b was determined spectrophotometrically 
according to an absorbance index of 13.2 (280 nm) (32). 
The partly purified recombinant y was determined with a 
densitometer, as described by (14), except that the 
purified truncated 71.300 was used as a standard. 
Strains. E. coli strain BL21(DE3) was used to express 
the PhK 7 subunit gene under the control of the T7 promoter 
(18). The E. coli strain TG-1 was used to amplify plasmid 
and to produce single-strained template DNA for mutagenesis 
(19) . 
DNA Manipulations. A series of synthetic primers were 
synthesized in the nucleic acid facility at Iowa State 
University. Manipulations of DNA were carried out according 
to standard procedures (22) . Plasmid DNA was digested with 
restriction enzymes, according to the manufactures' 
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recommendations (New England Biolabs or Promega). 
Restriction fragments were isolated from agarose gel by 
excising the desired band and isolating the DNA by the 
"glass milk" method (21). Single-strained DNA was prepared 
from pUC118-based phagemids (19). Oligonucleotide-directed 
site-specific mutagenesis was performed using an Amersham 
commercial kit (44). Mutations were identified by 
restriction enzyme analysis and verified by sequencing. 
Sequenced mutants were subcloned into PET-11a and 
transformed into BL21(DE3) cells. 
Construction of the Plasmid for Gene Expression in E .  
coli. Plasmid pGPK4 (11) was digested with the restriction 
enzymes ECoRI and HindiII to produce a 1.2-kilobase (kb) 
fragment that contained the coding region of the PhK y 
subunit gene and was subcloned into pUCllS. A Ndel 
restriction site at the 5' end of the cDNA was constructed 
by oligonucleotide-directed specific mutagenesis. The 
resultant plasmid was designated pUCG386. A series of 
truncated 7 genes were generated by oligonucleotide-
directed specific mutagenesis with stop codons introduced 
into the pUC386 at the 3' end of the cDNA at positions 353, 
341, 331, 316, 300, 290, and 276. A diagrammatic summary 
of the truncated forms of the y subunit appears in Figure 
lA. Mutations were verified by DNA sequence analyses. The 
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resulting plasmids were referred to as pUC353, pUC341, 
pUC331, etc. All these plasmids (full-length wild-type and 
seven other mutants) were digested with Ndel and HindiII. 
The 1.2-kb Ndel-Hindlll fragments containing the 7 subunit 
genes (wild-type and mutants) were isolated and ligated to 
the expression vector pET-lla (18), which had been digested 
with Ndel and Hindlll, to form plasmids pPKG386, pPKG353, 
PPKG341, PPKG331, pPKG316, pPKG300, pPKG290, and pPKG276. 
The nucleotide sequences of the entire 7 subunit coding 
regions (wild-type and mutants) were confirmed by 
sequencing. No mutations were found. All plasmids, 
pPKG386, PPKG353, pPKG341, pPKG331, pPKG316, pPKG300, 
pPKG290, and pPKG276, were transformed into E. coli 
BL21(DE3) cells. 
Expression and Purification of the Inclusion Bodies. 
A single colony from the transformation plate was 
inoculated into 5 ml LB containing 100 fig/ml ampicillin and 
incubated with shaking for 3 hours at 37°C. This 5-ml 
culture was inoculated into 500 ml of the same medium and 
incubated at 37°C on a shaker at 200 rpm. When the 
absorbance at 600 nm reached 0.6, isopropyl jS-D-
thiogalactopyranoside (IPTG) was added to the culture to a 
final concentration of 0.4 mM. After 1.5 hours of 
induction, the culture was harvested by centrifugation (10 
Figure 1. lA (top) shows the diagrammatic representation of the PhK 7 subunit, 
which indicates the catalytic domain and two calmodulin binding domains. 
lA (bottom) summarizes the truncated forms of y. Deletions of the 7 gene 
have been introduced using site-directed mutagenesis and the 
corresponding amino acid sequences relative to the catalytic domain and 
calmodulin binding domains of y are indicated. 
Primary Structure of Phosphorylase Kinase y Subunit 
and Summary of the Truncated Mutants 
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min at 4 000 x g) and resuspended in ice cold deionized 
water (3 g/ml of cell). The cell suspension was lysed by 
passage through a prechilled French pressure cell twice at 
5000 lb/in. pressure. The cell lysate was centrifuged at 
12000 X g for 15 min at 4°C. The collected pellet was 
resuspended in 20 mM Tris-HCl (pH 8.0), 5 mM EDTA, and 0.2 
mg/ml lysozyme. The suspension was incubated for 1 hour at 
room temperature with shaking. Sodium deoxycholate was 
added to give a final concentration of 1 mg/ml (23). 
Incubation continued for another hour. The pellets were 
collected by centrifugation at 12000 x g for 15 min at 4°C 
and resuspended in 50 mM Tris-HCl (pH 8.0) . Next MgClg, 
MnClj, DNase, and RNase were added to yield final 
concentrations of 10 mM, 1 mM, 10 fig/ml, and 500 U/ml, 
respectively. After a 20 min incubation at room 
temperature, the reaction mixture was centrifuged at 12000 
X g for 20 min. The pellet was resuspended in 8% 
sucrose/50 mM Tris-HCl (pH 8.0)/50 mM EDTA/5% Triton X-100 
(STET) and incubated with shaking at 4''C overnight (24) . 
This extraction step may remove the proteolytic activity 
from the inclusion bodies (24). The supernatant was 
removed by centrifugation. The STET washing procedure was 
repeated and the pellet resuspended in 50 mM Tris-HCl (pH 
8.0)/5 mM EDTA for storage. The final isolated inclusion 
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bodies, or recombinant 7 s ,  were judged 60 to 80% 
homogeneous by SDS-PAGE (Figure IB). Generally, the 
purities of full-length wild-type and various truncated 
forms of J were similar at this stage. 
Solubilization, Renaturation, and Further 
Purification. Inclusion bodies (full-length wild-type and 
truncated forms of 7) were dissolved in 5 M guanidine 
HCl/50 mM Tris-HCl (pH 8.0)/5 mM EDTA/2 mM DTT. 
Undissolved particulate was removed by centrifugation, and 
the solution diluted to 0.3 to 1 mg/ml with the same 
guanidine HCl solution. This procedure increases the yield 
of refolded protein in the next step (unpublished 
observation). All the following procedures were carried 
out at 4°C. 
The recombinant 7 ,  in 5 M guanidine HCl, was renatured 
by diluting the guanidine HCl solution 10-fold with buffer 
R (50 mM Tris-HCl (pH 7.8)/50 mM Hepes/lO% glycerol/5 mM 
DTT/150 mM NaCl). Protease inhibitors (1 mM phenyl 
methylsulfonyl fluoride, 0.5 mg/L Leupeptin, and 0.7 mg/L 
pepstatin) were added. Successful refolding requires low 
temperature and long-term incubation (14) . To establish 
the best conditions for renaturation, the time course of 
the renaturation of 7 and truncated 7 forms from 5 M 
guanidine HCl was studied. Figure 2 shows the renaturation 
Figure 1. IB shows the SDS-PAGE profile for partly 
purified inclusion bodies (full-length wild-
type and seven truncated forms of y). 
Molecular weight markers and PhK isolated from 
rabbit skeletal muscle are shown in the left 
and right lanes, respectively. 
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of truncated 71.300- The activity of truncated 71.300 reached 
a maximum when incubated on ice for at least 12 hours. A 
similar reactivation curve of full-length wild-type 7 was 
obtained with maximum reactivation reached at 12 hours 
(data not shown). The renatured recombinant 7s were 
centrifuged to remove the precipitated proteins and 
concentrated on centriprep-30 centrefugal concentrators 
(Amicon) to approximately 0.5 to 1 mg/ml. To obtain the 
pure active protein, neutral saturated ammonium sulfate was 
added to the renatured recombinant 7s (full-length wild-
type and truncated forms) to 50 to 70% saturation. This 
procedure can remove the proteins from guanidine HCl. The 
ammonium sulfate precipitate was collected by 
centrifugation, dissolved in buffer Q (40 mM Tris (pH 7.5) 
/60 mM Hepes/lO % glycerol/50 mM NaCl), and dialyzed 
overnight against the same buffer. Precipitated proteins 
in the dialyzed samples were discarded by centrifugation. 
The soluble proteins were incubated at least 12 hours 
before loading on the Q-Sepharose column, which was first 
equilibrated with 5 bed volumes of buffer Q. After samples 
were loaded, the column was washed with 5 bed volumes of 
buffer Q. The bound proteins were eluted with a 80-ml 
linear gradient of NaCl (50-400 mM) in buffer Q. 1.5 ml 
fractions were collected. Fractions containing kinase 
Figure 2. The time course of renaturation. The reactivation of truncated 71.300 was 
started by diluting 5 M guanidine HCl with buffer R as described in 
MATERIALS AND METHODS. 
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activity were pooled. The purification of truncated 71.300 
on Q-Sepharose chromatography is shown in Figure 3A. 
Approximately two-fold purification was obtained by means 
of this column. The recombinant truncated Y1.300 was 
purified to seeming homogeneity, as judged by SDS gel 
electrophoresis (Figure 3C). After purification, the 
active protein fractions could be stored at 0°C for a week 
without activity loss. 
An alternative approach was to apply the renatured 
truncated Yi.soo, diluted 20-fold with buffer Q, directly to 
the Q-Sepharose column without ammonium sulfate 
precipitation (Figure 3B). Two kinase fractions were 
obtained: one fraction with little and another with greater 
specific activity. The latter form had a specific activity 
approximately the same as that of a sample purified from 
the first method. This alternative method offered an 
efficient means, especially for screening the mutants, to 
purify the renatured truncated 71.300 to a purity and 
activity comparable to that obtained by the first method. 
The disadvantage is low recovery of active 
protein. 
Activity Assay. The kinase activity was determined by 
either the colorimetric method or the incorporation of 
into phosphorylase Jb or peptide substrates. The final 
Figure 3. Elution of the truncated Yi-aoo from the Q-Sepharose column. (A) Renatured 
Yi-3oo was precipitated with ammonium sulfate, loaded on the Q-Sepharose 
column, and eluted as described under MATERIALS AND METHODS. (B) 
Renatured Yi-aoo was loaded on the Q-Sepharose column directly and eluted. 
The first fraction was the higher activity fraction. The pure and 
active 71.300 was analyzed by SDS-PAGE (C) . 
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concentrations of the recombinant ys (diluted with buffer 
R) were between 0.01 and 0.1 fig/ml. The colorimetric 
method was similar to that described in (14), except that 
recombinant proteins were added to initiate the reaction. 
The determination of incorporation into phosphorylase Jb 
or peptide substrate was performed in an assay mixture 
similar to the foregoing, except that the [7-^^P]ATP was 
used as substrate. After incubation at 30°C for 5 min, the 
reaction mixture was spotted onto a square ET-31 or Whatman 
P-81 ion exchange filter paper, which was washed with 
trichloroacetic acid (TCA) solution or with phosphoric acid 
and subjected to liquid scintillation counting as described 
by (28, 29). ATPase activity was assay as described (39). 
For the determination of (for ATP and phosphorylase b) 
and values, initial rate determinations were carried 
out at pH 6.8 or at pH 8.2 for two time points, 1.5 minutes 
and 3 minutes, respectively. The final recombinant y 
concentrations were 0.01-0.1 ixg/ml. 71-290 and Y1.300/ for 
which the final concentrations in the assay were 0.01 
fig/ml, had final concentrations of 1 mg/ml BSA and 1 mM 
EGTA added to help stabilize the proteins. For each 
recombinant y, initial rates were determined at 
phosphorylase b concentrations varied from 10-80 fiM and ATP 
concentrations varied from 50-400 /xM. Each experiment 
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involved contained 50 data points (5x5x2 time points). All 
experiments were repeated at least three times using at 
least two different enzyme preparations. 
RESULTS Aim DISCUSSION 
Expression of PhK y Subunit and Other Truncated 
Mutants. We have expressed the PhK 7 subunit (full-length 
wild-type and truncated mutants) in a T7 RNA polymerase-
dependent expression system (18). The coding sequences for 
the 7 and other mutants were placed behind a bacteriophage 
T7 promoter. The expressions of resulting plasmids are 
under the control of the T7 promoter and can be induced by 
addition of IPTG to the culture medium. E. coli BL21(DE3) 
containing pPKG386 synthesized recombinant full-length 
wild-type 7 at a level of about 15 to 20% of total cellular 
proteins. The overexpressed recombinant 7, however, was 
mainly an insoluble aggregate known as an inclusion body 
(35, 36). No kinase activity was found in the insoluble 
fraction. Several attempts were made to obtain soluble 
protein, but significant amounts of the soluble 7 never 
were obtained for further studies (unpublished 
observation). The truncated mutants also were expressed as 
inclusion bodies at levels comparable to those found for 
full-length wild-type 7 .  
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Solubilization, Renaturation, and Further 
Purification. The specific activity (at pH 8.2) of full-
length wild-type 7 and truncated 71.300/ when maximally 
renatured, represented 15 to 20% and 40 to 45%, 
respectively, of the molar specific activity per catalytic 
subunit of the nonactivated PhK (specific activity of 
nonactivated PhK/4 (subunit of 7). After renaturation, the 
recombinant proteins were subjected to further purification 
by ammonium sulfate precipitation and to Q-Sepharose 
chromatography, as described in MATERIALS AND METHODS. At 
the final stage, the specific activity of the truncated 71. 
300 was increased five- to eight-fold with a 40 to 45% 
recovery of enzyme activity. Similar purity and activity 
were obtained with truncated 71.290- Densitometry was used 
to scan the other recombinant forms of 7 (either full-
length wild-type or five other truncated forms), which were 
precipitated during these processes, and purity varied from 
30 to 70%. Protein concentrations of 71.300 as great as 20 
mg/ml have been achieved. Thus, this enzyme form is 
suitable for physical studies such as NMR spectroscopy. 
Activity Assay and Kinetic Analyses. Activation of 
PhK caused by limited chymotryptic digestion or by 
expressed recombinant forms has been observed (10, 12, 13). 
What causes the activation is unclear, but the generation 
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of constitutively active -yi-zge (10, 13) might be indicative 
of the loss of an inhibitory domain. To test for the 
presence or absence of an inhibitory domain or a 
pseudosubstrate binding region in the C-terminal region of 
7 (30, 31), two strategies, limited proteolysis and 
deletion mutations, have been applied. First, unlike 
chymotryptic digestion of PhK, partial tryptic and 
chymotryptic digestion of recombinant full-length wild-type 
7 did not cause the activation probably because the 
structure of the 7 subunit is comparatively resistant to 
cleavage (results of SDS profile not shown). Second, seven 
deletion mutants were generated. The specific activity of 
these truncated mutants varied. Data showed that 71.353 and 
71-341 had 113% and 86% of the relative specific activity of 
full-length wild-type 7, respectively. Because both 71.353 
and 7i.34i had similar specific activity compared with the 
full-length wild-type 7, we did not characterize these two 
recombinant 7s any further and assumed that they had kinase 
properties similar t o those of the full-length wild-type 7 .  
Instead of activation, the specific activity of 71.331 was 
considerably less than that o f the full-length wild-type 7  
(only about 50%) . Thus, it seems unlikely that 7333.353 is 
the candidate for the pseudosubstrate binding site at the 
C-terminal region, as originally suggested by Kemp and 
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Pearson (30) . Three recombinant truncated 7 s ,  Ti-ais» Ti-3oo» 
and Ti.290 / however, had approximately two-fold greater molar 
specific activity than did full-length wild-type 7. A 
similar constitutively active fragment, 7i.29b/ derived from 
limited chymotryptic digestion of PhK (10) or from the 
recombinant form (13), exhibited catalytic activity similar 
to that of these three recombinant truncated 7 s .  
Kinetic analyses were undertaken to characterize 
further these truncated 7s with molar specific activities 
different from the activity of the full-length wild-type 
recombinant 7. Table 1 illustrates the kinetic data of the 
recombinant forms for each substrate, MgATP and 
phosphorylase b. The relative catalytic efficiency, 
^max/^(ATP) K„(phosphorylase Jb) , also is shown in the right 
column; full-length wild-type 7 is considered 100%. The 
interactions of these truncated mutants with both 
phosphorylase b and ATP varied nonsignificantly. The 
values (both substrates) for each mutant analyzed were 
quite similar. The main difference between these 
recombinant forms of 7 was in the values. The value 
for MgATP for each recombinant 7s studied was approximately 
75 /xM at both pH values. The values for phosphorylase b 
were approximately 18 /iM at pH 8.2. At pH 6.8, however, 
both the full-length wild-type 7 and the truncated 71.300 had 
Table 1. Summary of kinetic constants for recombinant 7*. 
Catalytic 
Recombinant (/xM) K„ (/iM) /xmol ^^P/min/ efficiency 
pH y forms (Phos. Jb) (MgATP) /nmol enz {V^^jK^s) 
00
 
to
 
TI-386 19 ± 1 77 ± 2 1.9 ± 0.02 100%® 
00
 
to
 
TI-331 17 ± 2 76 ± 2 0.9 ± 0.03 55% 
8.2 TI-316 16 ± 1 59 + 3 2.4 ± 0.09 195% 
00
 
to
 
TI-300 18 ± 1 79 ± 10 4.1 ± 0.03 224% 
00
 
TI-290 18 + 2 74 ± 4 4.3 ± 0.06 249% 
8.2 TI-276 20 ± 1 147 ± 7 0.2 ± 0.01 4% 
6.8 YI-386 36 ± 1 76 ± 2 2.0 ± 0.08 56% 
m
 
00
 
71-300 39 ± 2 82 ± 9 4.2 ± 0.04 102% 
* Activity was assayed as described in Materials and Methods. The 
relative catalytic efficiency, V„3^/k;„(ATP) Jf„(phosphorylase Jb) , is 
shown in the right column. 
* A caveat exists in the interpretation of kinetic parameters for 
Ti-3B6 because some proteolysis of this form was noted using antibody 
directed to y. The major band is -yi-aas - The presence of minor bands 
could contribute to the activity but not account solely for the V„ax 
shown in the table. 
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values twice as great as those at pH 8.2. This fact 
probably reflects both recombinant forms, having pH 6.8/8.2 
activity ratios of about 0.7-0.8. Judged from the 
catalytic efficiency, Yi.jie, Ti-aoo» and -yi-zso have a 1.9- to 
2.5-fold greater catalytic efficiency than do the full-
length wild-type y and a 3.5- to 4.5-fold greater 
efficiency than does the truncated 71.331. Because the 
greater specific activity for these three truncated 7 
reflects greater turnover rate, the data suggest that (1) 
there is an inhibitory domain(s) at the C-terminus of 7 
subunit which supports our hypothesis; (2) the active site 
region remains intact on these three truncated 7s; (3) the 
C-terminus region is not involved in substrate binding and 
catalytic reaction. The data regarding of a smaller of 
7i-33i indicated that the region between 301 and 331 can 
block the active site more efficiently than can that 
between 301 and 386. A greater for 71.315, although not 
as great as 71.300 and 71.290» could be interpreted as partial 
release from the autoinhibition imposed by the inhibitory 
sequence. Some residues between 317 and 331 probably are 
required for efficient inhibition. On the basis of these 
results, w e concluded only that at the C-terminus o f the 7  
subunit there is at least one inhibitory domain located 
between residues 301 and 331. This region (301-331) may 
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provide more complete inhibition than do residues 301-386. 
We were unable, however, to demonstrate whether there is an 
additional inhibitory region towards the C-terminal part of 
the molecule, or residues 331-386. If a second inhibitory 
region is present in the C-terminus region, these two 
distinct domains might have different affinities in the 
inhibition of the kinase activity of y. Several peptides 
corresponding to the C-terminus region are being prepared 
to establish a more specific location(s) of the inhibitory 
domain(s). 
To define the limits of the catalytic domain of the y 
subunit, the -yi-zvs form was constructed. This form has been 
suggested as the minimum sequence required for kinase 
activity (27) ; the truncated "yi-zve, however, had only 4% of 
the catalytic efficiency relative to the full-length wild-
type y. Kinetic analysis indicated that there was a two­
fold greater value for MgATP but a 10-fold decrease in 
the for "Yi-zie - The activity loss probably is not due to 
the removal of some important residues involved in 
catalysis, because 71.276 corresponds to the conserved kinase 
domain (7, 27). It is more likely that the loss of 
enzymatic activity in this instance is due to 
conformational instability of the molecule. The truncated 
Ti-290 is the smallest y which retains full 
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phosphotransferase activity yet to be constructed by 
genetic engineering. Some residues between 277 and 290 
probably are important for the stability of the entire 
enzyme. 
Characterization of Expressed Recombinant y. Because 
all the recombinant proteins have similar values, we 
tested whether Yi.jso and Yi-aoo have properties similar to 
those of the full-length wild-type 7. If these two 
truncated forms have properties similar to those of the 
full-length wild-type y and the nonactivated PhK isolated 
from rabbit skeletal muscle, we thought that we could use 
the two truncated forms as model enzymes with which to 
study the catalytic properties of the PhK y subunit. 
Inspection of the primary structure of the PhK y 
subunit suggests that truncations, A291-386 and A301-386, 
eliminated potential calmodulin binding sites in the C-
terminal region of the kinase. Evidence for this is 
derived from the presence of two calmodulin binding sites 
in the C-terminal region (9) and the observation that the 
catalytically active fragment 7i.29b/ isolated from limited 
chymotrypsin digestion of PhK (10) or from E. coli (13), 
showed no Ca^*/calmodulin activation. We tested the 
Ca^Vcalmodulin responses of the recombinant full-length 
wild-type y and truncated forms, Y1.290 and Ti-aoo. As 
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expected, both recombinant truncated forms showed a lack of 
Ca^Ycalmodulin activation. On the contrary, full-length 
wild-type y showed 35-75% activation by Ca^Ycalmodulin. 
The data confirmed that the interaction with calmodulin 
requires residues in the C-terminus of y. Additionally, 
unlike PhK, a Ca^"'-dependent enzyme, all three recombinant 
7s showed Ca^*-independent activity (with the presence of 1 
mM EGTA). The data suggested that the isolated recombinant 
7s have properties similar to those of the 7 isolated from 
rabbit skeletal muscle (14), or from other expression 
systems (13, 16, 17). 
Figure 4 illustrates the effects of Mg^ and Mn^" on 
full-length wild-type 7 and truncated 71.290 activities in 
the presence of 0.2 mM ATP. Metal-ATP mixtures activated 
both full-length wild-type 7 and truncated 71.290-
Additional free Mg^* activated both forms of 7 as it did 
with 7 isolated from rabbit skeletal muscle (15). The 
maximum activation of full-length wild-type o r truncated 7  
by Mg2+ was observed at approximately 5 mM excess above 
that chelated to ATP. The result implicated the presence 
of a free metal ion binding site, or a second metal ion 
binding site, in addition to the requirement for a metal 
chelated ATP. Free Mn^*, on the other hand, caused the 
inhibition of both forms of recombinant 7. The same 
Figure 4. The effect of divalent metal ions on recombinant y activity. The full-
length wild-type y (A) and truncated Y1.290 (B) were assayed at pH 8.2. 
The final [7-"?]ATP concentration was 0.2 mM. The assay mixtures 
contained different concentrations (0-15 mM) of divalent metal ions. 
(A) 
120 
100 
30 
60 Mn 
40 
20 
0 
0 
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(B) 
120 
2 4 6 8 10 12 14 
Metal ion conc. (mM) 
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inhibition pattern was observed in y isolated from rabbit 
skeletal muscle (15) . Similar results, activation by 
and inhibition by free Mn , were observed with truncated 
Ti-3oo- The similarities in metal ions requirements among 
7i-386/ 7i-3oo/ and 7i.29d suggestcd that the metal ions binding 
site(s) are not in the C-terminal region. 
ATPase activity has been observed in several different 
protein kinases including cAPK (37, 38) and PhK (39). To 
clarify how metal ions may regulate the activity of PhK, a 
study was undertaken of the ATPase activity of truncated 
Ti-3oo- Interestingly, this form of the enzyme also showed 
ATPase activity with Mg^* and Mn^*, but free Mn^* (up to 15 
mM for pH 8.2 and 20 mM for pH 6.8) had essentially no 
inhibitory effect (Figure 5). Although it is not proven 
what limits the reaction with PhK, it is known that free 
metal ions also inhibit cAPK (45), and it has been 
suggested that inhibition is due to a rate limiting 
dissociation of the metal-ADP complex with peptide as 
substrate (40, 41, 42). The lack of inhibition when water 
is the substrate suggests to us that metal-bound ADP can be 
released easily from the enzyme under this condition but 
not so in the presence of peptide or protein. 
The pH profiles of the recombinant full-length wild-
type 7 and truncated 71.300 appear in Figure 6. The data 
Figure 5. The effect of divalent metal ions on ATPase activity of truncated 71-300 • 
The ATPase activity was assayed at pH 8.2 (A) and pH 6.8 (B) using 
different concentrations of divalent metal ions. 
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indicated that both forms of 7 have indistinguishable pH 
dependencies in the pH range between 6 and 9 and pH ratios 
(specific activity at pH 6.8 to specific activity at pH 
8.2) approximately 0.7 to 0.8. Results were consistent 
phosphorylate the 9-18 peptide substrate but not Kemptide 
with those obtained with the y subunit isolated from the 
rabbit skeletal muscle (15). The other truncated forms of 
7 also had a pH ratio of 6.8/8.2 about 0.7 to 0.9. 
Several proteins reported to be phosphorylated by PhK 
were used to characterize the substrate specificities of 
the recombinant 7, both full-length wild-type and truncated 
forms. The recombinant proteins phosphorylated myelin 
basic protein, K-casein, troponin complex, isolated 
troponin T and troponin I (data not shown). The specific 
activity of PhK, full-length wild-type, and truncated 71.300 
with troponin I as substrate was six- to seven-times 
greater than the specific activities with troponin T as a 
substrate. Similar results were reported by Kee and 
Graves, who had used the free 7 subunit isolated from 
rabbit skeletal muscle (15). 
The 7  subunit and the catalytic subunit of cAPK share 
sequence homology at the catalytic domain, but these two 
enzymes display several other differences, such as 
substrate specificities. With respect to substrate 
Figure 6 .  The effect of pH on recombinant y activity. The full-length wild-type 7 
(A) and truncated Y1.300 (B) were assayed according to MATERIALS AND 
METHODS, except that buffer A (0.25 M Hepes, 0.25 M Tris, pH 8.6 or pH 
6.8, and 0.6 mM CaClz) was replaced with a different buffer to adjust to 
the indicated pH. 
Specific Activity (%) 
Specific Activity (%) 
L3 
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specificity, PhK only phosphorylated Ser 14 in 
phosphorylase h, and a 9-18 peptide which is derived from 
phosphorylase b sequence (29), but not kemptide, a 
substrate of cAPK. We also used peptide substrates to 
examine the substrate specificities of both full-length 
wild-type and truncated 71.300- Both recombinant y forms can 
(unpublished observations). The data clearly indicate that 
both recombinant 7 forms are different from the catalytic 
subunit of cAPK in substrate specificities. The results of 
substrate specificities using peptide substrates also were 
consistent with the results of PhK from rabbit skeletal 
muscle that were reported earlier (29). 
Truncated forms of y (either 71.290 or 71.300) have 
several advantages over full-length wild-type 7: (1) these 
two truncated 7s have the same for both substrates as 
does the full-length wild-type 7 but have greater 
values; (2) these two truncated 7s have greater specific 
activities at pH 6.8 and at pH 8.2 than does the full-
length wild-type 7; (3) both truncated 7s can be recovered 
with greater purity and higher yield than the full-length 
wild-type 7. Moreover, high concentrations of truncated 
7I-3OO can be achieved (10-20 mg/ml) . These two forms of 
truncated 7 therefore can be used as model kinases with 
which to study the substrate specificities, catalysis, and 
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Structure of the PhK y subunit. 
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FOOTNOTES 
^ The charge to alanine and charge reversal scanning 
mutations were also used to explore peptide specificity 
determinants of y (Cox et al., manuscript in preparation). 
^ The truncated wild-type "Yi-soo will be referred to as wild-
type 7. We will use mutant enzymes to represent truncated 
mutated 71.300 forms in this study. 
^ We have shown that peptide PhK13 (7302-326) (Dasgupta et al. 
1989) is a competitive inhibitor for phosphorylase b and a 
noncompetitive inhibitor for ATP; ADP is a competitive 
inhibitor to ATP and a noncompetitive inhibitor to 
phosphorylase jb. The results suggest that recombinant 71.300 
has the random bi bi mechanism (Huang & Graves, manuscript 
in preparation). 
* The results of computer simulation were provided by Drs. 
Jianhua Zheng and Sarah Cox. 
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SUMMARY 
Phosphorylase kinase (PhK) and truncated y subunit, 
denoted -yi-soo, can phosphorylate seryl and tyrosyl residues 
dependent on the metal ion (Yuan C.-J., Huang, C. F., & 
Graves, D. J. (1993) J. Biol. Chem. 268, 17683-17686). 
Recombinant Y1.300 was used to explore its dual specificity 
and the location of the metal ion binding sites by using 
site-directed mutagenesis. Two approaches were taken to 
generate 26 mutants. First, based on the crystal structure 
of cAMP-dependent protein kinase (cAPK), the invariant 
Asn^®® and highly conserved Asp^®®-Phe^®®-Gly^''° residues were 
mutated. Changes included production of N155H, D168E, 
D168N, F169R, G170V, G170I, G170L (less than 1% of 
enzymatic activities were found in these mutants), F169W, 
and G170A mutants. Second, charge to alanine and charge 
reversal scanning mutations were used to probe the metal 
ion binding sites. Two mutants, ElllK and E154R, showed 
very different metal ion response compared to wild-type 7 
and were further characterized. The mutants, F169W, G170A, 
ElllK, and E154R had 15%, 5%, 8%, and 25% specific activity 
relative to wild-type 7, respectively. The folding pattern 
of wild-type and mutated enzyme forms of 7 was determined 
by photoacoustic infrared spectroscopy. Conformational 
disruptions were found in G170V, G170I, and G170L mutants. 
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but the conformation of the rest of the mutants was similar 
to that of wild-type 7, suggesting that the loss of 
enzymatic activities of these mutants was not because of 
incorrect refolding. Kinetic analyses of mutants indicate 
that Asn^^® and Asp^®® residues influence maximal velocity 
and that Glu^^^, Glu^", Phe^", and Gly^'" residues influence 
binding of MgATP and phosphorylase b. The interactions of 
divalent cations, Mg^* and Mn^*, with ElllK, E154R, N155H, 
F169W, and G170A mutants were different from those with the 
wild-type, suggesting that Glu^^^, Glu^", Asn^®®, Phe^®®, and 
Gly"° contribute to the character of the metal ion binding 
sites. Our results suggest that the metal ion binding 
sites reside between the D^®®FG loop and the KPE^"N 
loop, similar to the metal ion binding sites in cAPK. The 
tyrosine kinase activity of 71.300 in the presence of Mn^* 
was increased in E154R (251%), unchanged in ElllK, F169W, 
and G170A, and reduced in N155H (5%). Typically, the 
mutations had a more pronounced effect on serine kinase 
activity than on tyrosine kinase activity. The activity 
ratio (tyrosine kinase activity to serine kinase activity) 
increased in the mutants, suggesting that these five 
residues have different roles in the two activities. Our 
results support the view that different conformational 
states induced by metal ions are important for dual 
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specificity. 
INTRODUCTION 
Phosphorylase kinase (PhK) catalyzes the 
phosphorylation and activation of glycogen phosphorylase b. 
The subunit composition in white skeletal muscle is 
(a, 18,7,0)4 with a molecular mass of about 13 00 KDa 
(reviewed in Pickett-Gies & Walsh, 1986; Heilmeyer, 1991). 
The y subunit is catalytically active (Kee & Graves, 1986), 
and its N-terminal region shares sequence homologous with 
the catalytic domains of other protein kinases (Hanks et 
al., 1988). We have expressed PhK y subunit (full-length 
and truncated forms) in E. coli (Huang et al., 1993). A 
truncated form, 71.300/ has several advantages over full-
length 71-386» such as greater purity and greater turnover 
number, yet has the same K^, values as full-length 7 (Huang 
et al., 1993). Furthermore, the truncated form has the 
same metal-ion dependence as the full-length 71.336 (Huang et 
al., 1993). We show in this work that the truncated 71.300 
form can be used to study the role of specific residues 
involved in catalysis and metal-ion responses of the PhK 7 
subunit. In this study, all the mutant enzymes are the 
truncated 71.300 form. 
Previous studies have demonstrated that free Mg^* 
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activates 7 and that free Mn^*, on the contrary, inhibits 
its serine kinase activity (Kee & Graves, 1987; Cox & 
Johnson, 1992; Huang et al., 1993). The data revealed the 
existence of a free metal ion binding site, or second metal 
ion binding site, in addition to the requirement for a 
metal chelated ATP, the first metal ion binding site. 
However, these two metal ion binding sites are not well 
characterized in y. Recently, several reports have shown 
that some protein kinases have dual-specificity (reviewed 
in Lindberg et al., 1992). PhK is among them (Yuan et al., 
1993). The evidence for most dual-specificity kinases is 
derived from autophosphorylation studies, phosphotyrosine 
antibody screening, and peptide substrate phosphorylation 
(Lindberg et al., 1992). However, PhK and 7 have the 
unique property that the dual specificity is modulated by 
metal ion. 
In cAPK, there are two metal ion binding sites. 
Unlike the 7 subunit, binding of the free metal ions, such 
as Mg2+ and Mn^*, at the second metal ion binding site 
inhibited the kinase activity of cAPK (Armstrong et al., 
1979). From X-ray crystallographic studies of the cAPK, 
Zheng et al. (1993a,b) have shown that the invariant 
residue, Asp^®'* (equivalent to Asp^" in 7) , participates in 
catalysis by directly chelating Mg^* (first metal ion 
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binding site) of the MgATP complex and is also involved in 
the binding of free metal ions. This invariant Asp^®"* 
residue is in the conserved DFG loop of the protein kinase 
family (Hanks et al., 1988). Knighton et al. (1991a,b) 
showed that the DLKPEN"^ loop is involved in catalysis, 
peptide substrate and MgATP binding, and free metal ion 
binding. Although Zheng et al. (1993a,b) showed that the 
invariant Asn"^ (equivalent to Asn^®® in 7) interacts with 
the metal ion in cAPK, this residue is not responsible for 
the binding of the metal ion in the crystal structures of 
the CDK2 and its MgATP complex (De Bondt et al., 1993) . 
There is, however, a lack of experimental data to address 
the function of this invariant residue. Site-directed 
mutagenesis was performed to investigate the role of this 
residue. We constructed a series of mutations in 7 at the 
highly conserved DFG region to investigate (a) the roles of 
specific residues, Asp^®®-Phe"®-Gly"°, within the catalytic 
domain of 7 subunit and (b) whether the change of the 
nearby residues would alter the requirement for, or 
response to, divalent metal ions, particularly because we 
reported that the enzyme has tyrosine kinase activity in 
the presence of Mn^* (Yuan et al., 1993). To search for 
the other essential negatively charged residue(s) in the 
large lobe of the kinase domain that might participate in 
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chelating metal ions, we used charge to alanine and charge 
reversal scanning mutations.^ Seventeen mutants were 
generated, and the two that had significant differences on 
the metal ion response were further characterized. 
All the mutant proteins were purified to homogeneity, 
and their secondary structures were analyzed by 
photoacoustic infrared spectroscopy, which has been 
utilized recently in our laboratory to evaluate the 
secondary structures of proteins (Luo et al., 1994). This 
is the first example for the use of Photoacoustic infrared 
spectroscopy in the analyses of mutant proteins. 
MATERIALS AND METHODS 
Materials. Restriction enzymes were purchased from 
New England Biolabs or Promega. Q-Sepharose was obtained 
from Pharmacia, and dithiothreitol (DTT) was from Pierce. 
[Y_32p]ATP and [^-^^PlGTP were purchased from ICN 
Biomedicals. The rest of reagents were purchased from 
Sigma. Phosphorylase b was prepared from rabbit skeletal 
muscle as described in Fischer & Krebs (1958), and residual 
AMP was removed by treatment with acid-washed Norit. The 
peptide substrate (Lys-Arg-Lys-Gln-Ile-Ser-Val-Arg-Gly-Leu) 
corresponding to the amino terminal residues 9-18 of 
phosphorylase Jb was synthesized at the Iowa State 
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University protein facility and purified by reverse-phase 
HPLC C-18 column. The cDNA of PhK 7 subunit was from 
rabbit skeletal muscle (Huang et al., 1993) . 
DNA Manipulations and Oligonucleotide-Directed Site-
Specific Mutagenesis. Standard DNA manipulations were 
carried out as described (Sambrook, 1989). 
Oligonucleotides used in site-directed mutagenesis were 
synthesized in the nucleic acid facility at Iowa State 
University. For construction of mutant forms of Y1.300/ the 
single-stranded DNA of pUCG300 plasmid (Huang et al., 
1993), which encodes the 1-300 amino acids of PhK y, was 
prepared by standard procedure (Vieira & Messing, 1987) . 
The isolated single-stranded DNA was used as the template 
for site-directed mutagenesis by using an Amersham 
commercial kit (Sayers et al., 1988). Mutations were 
identified by restriction enzyme analysis and then verified 
by sequencing. The coding sequence for the wild-type y and 
its mutant forms^ was subcloned into pET-lla expression 
vectors (Studier & Moffatt 1986) and transformed into 
BL21(DE3) cells, which were used for expression of wild-
type and mutant forms of y (Huang et al., 1993). 
Expression and Purification of Mutant ys. Wild-type 
and mutant forms of 7 were expressed by using the T7 RNA 
polymerase-based expression system (Studier & Moffatt, 
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1986) as previously described (Huang et al., 1993) . The 
wild-type and mutant enzymes were expressed at a high level 
as inclusion bodies. None of the mutants generated by 
oligonucleotide site-directed mutagenesis had an effect on 
protein synthesis or solubilization of the expressed mutant 
enzymes. The inclusion bodies of all 7 forms (wild-type 
and mutants) were isolated, solubilized, renatured, and 
further purified by ammonium sulfate precipitation, 
followed by Q-Sepharose chromatography as previously 
described (Huang et al., 1993). All the recombinant 
proteins were purified to homogeneity as judged by SDS gel 
electrophoresis (data not shown). 
Photoacoustic Infrared Spectra Analyses. The final 
isolated wild-type and mutant enzymes were dialyzed against 
50 mM Tris-HCl (pH 7.5)/ 50 mM NaCl/ 10% glycerol/ 5 mM DTT 
and then concentrated to 1 to 1.5 mg/ml. Samples were 
prepared as a thin layer by spreading 1 to 2 pi (2 pg) of 
protein solution on a 7-mm-diameter small teflon membrane 
disk made from the window of the 3M disposable IR card (Luo 
et al., 1994). The Perkin-Elmer Model 1800 FTIR 
spectrometer and MTEC Photoacoustic Model 200 Photoacoustic 
detector were used to collect the photoacoustic infrared 
spectra. The spectra of each sample were obtained by 
scanning 2,000 cycles at a 0.05-cm/s optical-path-
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difference velocity with 2 cm'^ resolution. Two 
mathematical manipulations were used to extract the 
information on protein secondary structure contents from 
photoacoustic infrared spectra. Secondary derivative and 
curve-fitting methods were utilized as described by Luo et 
al. (1994) . 
Protein Concentration Determination and SDS-
Polyaery1 amide Gel Electrophoresis (SDS-PAGE). Protein 
concentrations were determined by the Bradford assay with 
commercially prepared reagents from Bio-Rad (Bradford, 
1976). SDS-PAGE was done in 10% acrylamide gel as 
described (Laemmli, 1970). 
Activity Assay. The seryl kinase activity of 7 was 
determined by incorporating of ^^P into phosphorylase b as 
previously described with some modification (Kee & Graves, 
1986; Yuan et al., 1993). The standard assay contained the 
final concentrations of 50 mM Tris, 50 mM HEPES, pH 8.2, 10 
mM MgClg, 10 mg/mL phosphorylase jb, and 1 mM [7-^^P]-ATP or 
1 mM [7-^^P]-GTP. The tyrosine kinase activity assay was 
using Angiotensin II and MnATP as substrates and described 
previously (Yuan, et al., 1993). In serine kinase 
activity, the and values of reactions with MgATP and 
phosphorylase b at pH 8.2 were determined by standard 
reciprocal plots of initial-rate data. The final 
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concentrations of wild-type and most mutant enzymes used in 
activity assay and kinetic analyses were 0.02-0.05 fxg/ml. 
For mutant N155H and D168N, 50 and 200 jug/ml were used, 
respectively. The initial rates were determined at 
phosphorylase b concentrations varying from 10 to 250 /xM 
and ATP concentrations varying from 50 to 1200 ixM. When 
GTP was used, the concentrations varied from 50 to 4000 /xM. 
For each mutant, the kinetic parameters were obtained 
varying the substrate concentrations from 1/2 K^, to 5 times 
K^. In the case of F169W mutant, the GTP concentrations 
were from 4 00 to 4000 /xM. All the experiments were 
repeated at least three times, and the samples were from at 
least two different preparations. 
RESULTS 
Properties of the Mutant Enzymes. To explore the 
roles of the conserved short stretch, Asp^®®-Phe^®®-Gly^''° 
(Table 1), mutations were introduced into the coding 
sequence of 71.300 • Me asked whether a larger but negatively 
charged glutamic acid (D168E) and a similarly sized but 
uncharged asparagine (D168N) could functionally substitute 
for Asp^®® in y. Incorporation of either D168E and D168N 
into 7 nearly abolished its serine phosphotransferase 
activity (both mutants showed less than 1% specific 
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Table 1. Sequence Alignment of PhK 7 Subunit with Various 
Protein Kinases. Some mutated positions are indicated as 
bold face: E"'', D"®, and G"°. The regions 
that distinguished serine kinases and tyrosine kinases are 
underlined. 
Protein kinases Sequences 
111 154 ICS 
PhK- 7 GGEMF- -RDLKPgJ7ILLDDDM- - LTDFGFS 
cAPK KGgLF- -RDLKPEJJLLIDOQG- -VTDFGFA 
CasK II NTDFK- -RDVKPHJfVMIDHEN- -LIDFl^QLA 
EGF R FGCLL--RDLAAJWVLVKTPO--ITDFGLA 
Insulin R HGDLK--RDLAAEf^CMVAHDF--IGDFGMT 
pp60''-=''° KGSLL- -RDLRAAZflLVGENL- -VADFGLA 
Table 2. Specific Activities of Wild-type and Some of Its Mutant Forms. 
Ser Kinase Activity^ (%) Ser Kinase Activity(%) Tvr Kinase Activity^ (%) 
MgATP/Phos. Jb MgGTP/Phos. b MnATP/Angiotensin II 
Wild-type 100 4 100 
ElllK 8 - 78 
E154R 25 - 251 
N155H < 1 - 5 
D168N < 1 - < 1 
F169W 15 0.5 85 
G170A 5 - 82 
® The serine kinase specific activity of wild-type y was determined in the 
presence of 50 mM Tris (pH 8.2), 50 mM Hepes, 5 mM DTT, 10 mM MgClg, 10 mg/mL 
Phos. jb, and 1 mM [7-^^P]ATP or 1 mM [7-^^P]GTP. The wild-type specific 
activity (3.5 fimol ^^P/min/nmol enz) was used as 100%. 
^ The tyrosine kinase activity was assayed in the presence of 50 mM Tris (pH7.9), 
50 mM PIPES, 10% glycerol, 3 mM MnClg, 1 mM [y-^^PjATP, and 2 mM Angiotensin II. 
The wild-type specific activity (0.25 nmol ^^P/min/nmol enz) was used as 100%. 
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activity when compared with wild-type) as measured in the 
standard assay. 
Two mutants of y were made in Phe^®® position. Phe was 
changed to Trp (F169W) because casein kinase II (CasK II) 
has this sequence and this enzyme can utilize GTP almost as 
efficiently as ATP (reviewed in Pinna, 1990). The F169W 
mutant had 15% the activity of the wild-type (Table 2). 
Incorporation of Trp did not stimulate phosphotransferase 
activity with GTP (Table 2). Somewhat greater activity was 
seen with MnGTP than with MgGTP for both wild-type and the 
F169W mutant (data not shown). To alter the charge 
character of the region, Phe was changed to Arg (F169R). 
This mutant enzyme was essentially inactive. 
The X-ray crystal structure of cAPK ternary complex 
shows that the invariant Gly at position 170 is located at 
the interface between the small and large lobes, where it 
is surrounded by several hydrophobic residues (Knighton et 
al., 1991a,b). To determine whether this invariant glycine 
could be replaced by larger, hydrophobic residues, alanine 
(G170A), valine (G170V), isoleucine (G170I), and leucine 
(G170L), these mutants were prepared. Of the mutant 
proteins obtained, only the G170A mutant had appreciable 
kinase activity, 5% relative to wild-type y (Table 2). The 
other mutants showed less than 1% specific activity. 
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The N155H mutant was constructed to probe the function 
of the invariant Asn^^® residue. Less than 1% of serine 
kinase specific activity was found (Table 2). This is not 
surprising because of the invariance of this residue in the 
protein kinase family (Hanks et al., 1988). Because this 
residue has been implicated in free metal ion binding in 
cAPK but not in CDK2, the metal ion dependence of N155H was 
tested and characterized. 
We used charge to alanine and charge reversal scanning 
mutations^ to search for other negatively charged 
residue(s) in the large lobe of the kinase domain that 
might participate in chelating metal ions; seventeen 
mutants were generated, including ElllA, ElllK, D114A, 
E118A, E124A/E126A, E136A, E154A, E154R, D159A, D160A, 
D161A, D186A, E189A/E193A, E197A/D202A, E210A, 
E253A/D255A/D256A, and D259A/D263A. Two of them, ElllK and 
E154R, with 8% and 25%, respectively, the activity of wild-
type Y (Table 2), had a different response to metal ions 
(see later in Fig. 2). Because the substrate, 
phosphorylase Jb, also binds free metal ions (Graves & Wang, 
1972), we wanted to exclude the possibility that this 
unique metal ion response might come from phosphorylase b. 
We used a peptide substrate, corresponding to residues 9-18 
of phosphorylase Jb, as an alternative substrate lacking the 
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metal ion binding property for the same assay. Similar 
results were obtained (data not shown), suggesting that the 
observed metal ions responses did not derive from 
phosphorylase b. These two enzyme mutants were further 
characterized. 
Photoacoustic Infrared Spectroscopy Analyses. Less 
than 1% of enzymatic activity was found with the N155H, 
D168E, D168N, F169R, G170V, G170I, and G170L mutant 
enzymes. The loss of enzymatic activity could be due to 
several factors including the involvement of the mutated 
residues in chemical reaction, substrate binding, or 
conformational stability. To evaluate possible 
conformational changes induced by mutation, photoacoustic 
infrared spectroscopy was used to study the folding of 
recombinant 7 forms (wild-type and mutants). Using this 
technique, we have shown previously that this method is 
very sensitive and that the secondary structure contents 
obtained by this technique are similar to those of the CD 
measurement (Luo et al., 1994) 
Photoacoustic infrared spectra were analyzed with 2 ng 
of the individual mutant proteins {Materials and Methods) . 
There were no significant differences either in the spectra 
or the calculated secondary structure content of the mutant 
enzymes, including D168N (Fig. lA), ElllK, E154R, N155H, 
Figure 1. Photoacoustic Infrared Spectroscopy Analyses of 
Y and Its Mutant Forms. (A) Comparisons of 
photoacoustic infrared spectra of wild-type 
(solid line) and D168N mutant (dash line); (B) 
Comparisons of photoacoustic infrared spectra of 
wild-type and its mutants forms in the amide I 
region; (C) Results of curve-fitting of G170V 
mutant (top) and wild-type (bottom). 
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D168E, F169R, F169W (data not shown), and G170A (Fig. IB), 
when compared with the wild-type 7. The spectra of G170V, 
G170I, and G170L, however, were obviously different in the 
amide I band region when compared with wild-type enzyme 
(Fig. IB). Spectral differences, especially assignments of 
/3-sheet structure, are illustrated in Fig. IC with curve-
fitting comparisons of wild-type and G170V mutant. The 
significant spectral differences suggest conformational 
disruptions in these mutants. The calculated secondary 
structure contents, derived from mathematical manipulations 
of curve-fitting as described in Luo et al., 1994, indicate 
the gradually increasing /3-sheet structures of the mutant 
enzymes. The estimated 0-sheet content of wild-type y and 
G170A mutant was 33% and 31%, respectively. However, it 
increased to 53% for G170V, 65% for G170I, and 59% for 
G170L. The increasing 0-sheet contents of these mutants 
are coincident with decreasing levels of the a-helix and 
random coil contents. There were no significant 
differences in the percentage of turn structures. Clearly, 
the position of the invariant residue Gly^'® cannot 
accommodate larger residues, suggesting that one of the 
possible functions of this residue is involved in the 
structural integrity of the protein kinase family. 
Kinetic Analyses. Kinetic studies were undertaken to 
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determine why the mutants with folding similar to that of 
wild-type 7 had lower molar-specific activity. But the 
interpretation of the significance of the kinetic 
parameters is uncertain unless the kinetic mechanism is 
known. If the mechanism is random bi bi, dissociation 
constants can be calculated for the binding of the two 
substrates. Phosphorylase kinase was shown earlier to use 
a random bi bi kinetic mechanism (Tabatabai & Graves, 
1976), but studies with 7-calmodulin complex suggest a 
random or ordered mechanism (Farrar & Carlson, 1991; 
Sanchez & Carlson, 1993). Using dead end inhibitors, we 
found that the kinetic mechanism of the recombinant 71.300 is 
a random bi bi kinetic mechanism^ (Huang and Graves, 
manuscript in preparation). Therefore, studies were done 
with various protein and ATP to obtain different kinetic 
parameters. Because K„ values may not necessarily reflect 
binding character, the dissociation constants for the 
binding of phosphorylase b (Kia) and MgATP (Kib) were 
calculated from the linear secondary plots. Note that 
similar patterns (Table 3) are seen among values, Kia, 
and Kib values for most of the mutant forms, suggesting 
that Km values in these instances are a measure of binding, 
except that E154R has a 3-fold higher K„ for MgATP but a 
similar K^^ value to the wild-type. In this case, we 
Table 3. Kinetic Parameters^ of the Wild-Type 7 and Its Mutant Forms 
Recombinant Km(/xM) Km(/xM) Kia(^M) Kib{^M) Km(mM) Kib' (mM) (pmol 
Y forms (phos. jb) (MgATP) (phos. Jb) (MgATP) (MgGTP) (MgGTP) min/nmol enz) 
Wild-type 18 ± 1 79 ± 10 24 ± 3 105 ± 21 - - 4.1 ± 0.03 
ElllK 107 ± 8 305 ± 31 112 ± 12 319 ± 8 - - 0.4 ± 0.03 
E154R 113 ± 8 242 ± 9 75 + 5 160 ± 6 - - 6.0 ± 0.20 
N155H 26 ± 3 26 + 5 40 ± 5 39 ± 9 - - 4 .8x10'^ ± 0.2x10"^ 
D168N 23 ± 2 70 ± 4 24 ± 1 73 ± 1 - - 1 .1x10"^ ± 0.1x10"^ 
F169W 49 ± 4 290 ± 12 41 ± 4 243 ± 13 - - 6.5 ± 0.10 
G170A 178 ±14 344 ± 9 142 ± 4 274 ± 8 - - 0.8 ± 0.07 
Wild-type 76 ± 9 - 58 ± 6 - 0 .1 ± 0 .04 0.08 ± 0 .03 0.3 ± 0.04 
F169W 92 ± 10 - 86 ± 8 - 2 .3 ± 0 .4 2.2 ± 0 .3 0.7 ± 0.06 
Kinetic parameters are defined as: E + Phos. Jb = E-Phos. Jb, K^a,- E-Phos. Jb + 
ATP = E-Phos. jb-ATP, (ATP); E + ATP = E-ATP, Kit/ E-ATP + Phos. b = 
E-ATP-Phos. Jb, K^ (Phos. Jb) ; E + GTP = E-GTP, Kit'; E-Phos. b + GTP = 
E-Phos. jb-GTP, K^ (GTP). 
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conclude that mutation E154 to R does not influence MgATP 
binding. If the comparison is based solely on values, a 
wrong conclusion can be reached. Table 3 presents the 
results of the kinetic studies of wild-type and mutant ys 
(ElllK, E154R, N155H, D168N, F169W, and G170A) at pH 8.2 
for both MgATP and phosphorylase b. 
Comparison of the kinetic parameters of N155H and 
D168N mutants with the wild-type y showed similar K^, Kia, 
and Kib values for both substrates but a 850- and 4000-fold 
decrease in V^^x/ suggesting that Asn^^® and Asp^®® residues 
may have an important role in catalysis like cAPK. 
Interestingly, E154R and F169W mutants had higher Km 
values for both substrates, a 3-6 fold increase, but their 
Vmax values are essentially the same as values of the wild-
type enzyme. ElllK and G170A mutants showed an increase in 
Km values for both substrates, a 4- to 10-fold increase, 
but a 10- and 5-fold reduction in respectively. These 
mutants seem to have a less well-formed active site region 
than the wild-type but are competent enzyme forms. 
Kinetic analyses were also done with GTP as a 
phosphate donor with wild-type and the F169W mutant. In 
this instance, the K^ values (for phosphorylase b) suggest 
that the wild-type binds phosphorylase b more poorly than 
when ATP is present and that mutation of F169W causes no 
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further change. The F169W mutation, however, increased the 
Kn, for MgGTP 23-fold and caused a 2-fold increase in 
relative to the wild-type enzyme. 
Metal Ion Responses and the Second Metal Ion Binding 
Site. Earlier, it was found that free Mg^" activated the 
serine kinase activity of 7 but that free Mn^* inhibited 
(Kee & Graves, 1987; Cox & Johnson, 1992; Huang et al., 
1993) . In cAPK, Asp^®^ has been implicated as the residue 
involved in the chelation of Mg^* in the MgATP complex 
(Knighton et al., 1991a,b). Therefore, it was particularly 
relevant to investigate whether a change in the neighboring 
residues of Asp"® (or itself) would cause different effects 
of divalent metal ions on 7. Figure 2A shows the effects 
of these metal ions on the wild-type 7 when phosphorylase b 
is used as a substrate. Similar metal ion responses were 
found with both the D168N (Fig. 2B) and D168E mutants (data 
not shown). Both mutants, as well as wild-type 7, reached 
maximal activation at 5 mM Mg^*, and all exhibited the same 
inhibition pattern in the presence of free Mn^*. 
Unlike wild-type 7, the F169W, G170A, E154R, and ElllK 
mutants showed quite different metal ion effects (Fig. 2C, 
2D, 2E, St 2G) . A shift in the concentration required for 
maximal activation from 5 mM Mg^* to 10 mM is shown in Fig. 
2, indicating that all four mutants can be activated by 
Figure 2. Effect of Divalent Metal Ions on the Serine Kinase Activity of y and 
Mutants Forms. Serine kinase activities of (A) Wild-type, (B) D168N, 
(C) F169W, (D) G170A, (E) E154R, (F) N155H, and (G) ElllK were assayed 
at pH 8.2 as described in Materials and Methods except 0.2 itiM [-y-^PlATP 
and varied concentrations of MgClj or MnClj were used. The highest 
activity in each figure was used as 100% and relative specific 
activities were shown in Table 2. 
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free Mg^* but not as effectively as the wild-type enzyme. 
More direct evidence resulted from examining the effects of 
free Mn^% All mutants, F169W, G170A, E154R, N155H, and 
ElllK, displayed significantly inhibition patterns 
different from those of wild-type 7. Activation, instead 
of inhibition, was observed at low concentrations of Mn^* 
in all instances, especially G170A and ElllK, which had the 
highest activity in the presence of free Mn^* but not free 
Mg^*. Because of these results, the Glu^^^, Glu^", Asn^®®, 
Phe^®®, and Gly^^° residues are possibly very close to the 
metal ion binding sites or the side chain of the mutants 
pointed to the metal ion binding sites. Mutations on these 
five residues might induce a subtle, spatial configuration 
change around the metal ion binding sites and then cause 
these different metal ion effects. 
Metal Ion Response and Tyrosine Kinase Activity of 7 
Suhunit and Its Mutant Enzymes. Recently, we have reported 
that PhK and 7 are metal-ion dependent dual-specificity 
kinases (Yuan et al., 1993). Seven mutants, ElllK, E154R, 
N155H, D168E, D168N, F169W, and G170A, were assayed for 
their tyrosine kinase activity. With MnATP, D168N and 
D168E showed no tyrosine kinase activity, indicating that 
this residue is involved in phosphoryl transfer to tyrosine 
or serine. Wild-type enzyme and most mutant enzymes showed 
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low tyrosine kinase activity in the presence of (data 
not shown). E154R had a slightly higher tyrosine kinase 
activity than wild-type in the presence of Mg^*, but Mn^* 
still favored for tyrosine kinase activity (data not 
shown). Tyrosine kinase activity of wild-type 7 and its 
mutant forms has been analyzed with MnATP and is shown in 
Table 2. Interestingly, E154R had a 2.5-fold higher 
tyrosine kinase activity than wild-type enzyme. The higher 
tyrosine kinase activity of E154R was reflected by the 
increase of (Huang and Graves, unpublished result). 
DISCUSSION 
Eight mutants have been constructed to elucidate the 
possible roles of the conserved short stretch, Asp-Phe-Gly, 
found in the subdomain VII of protein kinases (Hanks et 
al., 1988). Several investigators have reported site-
directed mutagenesis of the invariant Asp residue (Moran et 
al., 1988; Gibbs & Zoller, 1991). The loss of enzymatic 
activity with the D168E and D168N mutants reported here was 
consistent with these other reports. Obviously, y does not 
tolerate well the conservative replacement in Asp^®® with 
respect to size or charge. From our kinetic analyses, we 
conclude that the invariant Asp^®® residue is involved in 
catalysis. This conclusion is supported by comparison of 
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the cAPK crystal structure. 
X-ray crystallographic studies of the cAPK ternary 
complex have shown that the invariant Asp^®^ residue 
(equivalent to Asp"® in 7) is involved in chelating Mg^* in 
the MgATP complex and free Mg^*. Both D168N (Fig. 2B) and 
D168E (data not shown) have metal ion responses identical 
to the responses of the wild-type 7. Because cAPK and y 
are structurally and functionally related proteins (Reimann 
et al., 1984), an analysis of the structure of the cAPK 
ternary complex was made, with substitution of invariant 
Asp^®^ with Glu and Asn to probe the spatial relationship 
between this invariant residue and the two metal ions. The 
results of computer simulation showed that these 
replacements did not enlarge the distance (D184N) or 
shorten the distance (D184E) to either metal ion* in cAPK 
(Zheng, Cox, and Taylor personal communication). Thus, we 
suggest that, even though the mutants have properties 
similar to the wild-type, Asp^®® of 7 is probably involved 
in binding of both metal ions. 
Because both Phe^®® and Gly"° are highly conserved in 
protein kinases, these two residues probably have a general 
function in the protein kinase family. The loss of 
enzymatic activity of the F169W mutant was not because of a 
gross conformational change, on the basis of photoacoustic 
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infrared spectrum, and was not involved in catalysis, on 
the basis of kinetic analyses. Because the Phe residue is 
spatially close to the MgATP binding site in cAPK, the 
higher K^, values for MgATP and phosphor y 1 a s e b might be 
indicative of the mutation causing changes in MgATP 
binding, which indirectly influences the phosphorylase b 
binding. 
The replacement of Phe"® by a positively charged Arg 
(F169R) greatly diminishes the activity. The X-ray 
crystal structure of cAPK shows that Phe is located at the 
interface between small and large lobes and is a member of 
the hydrophobic pocket. Introducing a hydrophilic residue, 
arginine, into this position might be unfavorable to the 
hydrophobic interactions in the region. Substitution of 
Phe with hydrophobic residues showed partial 
phosphotransferase activity. Similar mutation results were 
obtained in Cask II (Jakobi & Traugh, 1992) . In the 
recombinant Cask II a subunit, replacement of the 
hydrophobic Trp (equivalent to the position of Phe^®® in y) 
with Lys produced a mutant enzyme without kinase activity. 
Most protein kinases cannot utilize GTP (or use it 
only poorly) as the phosphoryl donor when compared with ATP 
(Bradford, 1976; Pocinwong et al., 1981). The DFG region 
is thought to be associated with MgATP binding (Sambrook et 
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al., 1989; Vieira & Messing, 1987) and the substitution in 
Cask II, Trp instead of Phe, might explain this unique 
feature of Cask II in using GTP. The F169W mutant of y was 
generated to probe the possibility of utilizing GTP, as 
well as ATP, as the phosphoryl donor. However, the higher 
Km and Kib values for MgGTP in the F169W mutant suggested 
that (a) the precise interactions between Phe^®® and the 
surrounding residues cannot be functionally replaced by 
another hydrophobic residue and that (b) the binding of 
MgGTP (or utilization of MgGTP as a phosphate donor) was 
not solely dependent on a single residue, Phe or Trp. The 
Phe residue helps to orient MgATP to facilitate phosphoryl 
transfer, but other residues may be responsible for the 
utilization of MgGTP both in Cask II and y. 
We did not observe any conformational disruption in 
the G170A mutant, but can clearly show a conformational 
change in other mutants at this position (G170V, G170I, and 
G170V). Increases in the size of the residue at this 
position might cause a perturbation of the structure of the 
catalytic core. Our kinetic data showed that the G170A 
mutant not only had a decreased V^ax, but also had increased 
K^, Kia, and Kit values for substrates. The invariant Gly 
residue probably helps to maintain the flexibility of the 
active site region needed for substrate entrapment and 
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product release. 
In cAPK (from Saccharomyces cerevisiae), Gibbs and 
Zoller showed that Glu^''^ and Glu^" (equivalent to Glu^^^ and 
Glu^^'* in 7) were involved in peptide substrate binding 
(Gibbs & Zoller, 1991a,b). A mutation at those positions 
in cAPK, E171A and E214A, showed a 90- and 126-fold 
increase in K^, values for peptide but no significant change 
in Km for MgATP or Unlike such dramatic increases in 
Km values, our kinetic data showed that ElllK and E154R 
mutants had a 5- and 3-fold increase in K^g values, 
respectively. Our findings argue that both positions (Elll 
and E154) are involved in phosphorylase b binding but may 
be not the identical interactions as cAPK with kemptide. 
The results suggest that these changes. Glu to Lys or Arg, 
perhaps, not only alter the phosphorylase b binding region, 
but also indirectly influence the binding of metal ion and 
MgATP (higher K^ for MgATP) . This might explain the 
observed metal-ion effects on ElllK and E154R (Fig. 2). 
The responses to metal ions of ElllK, E154R, N155H, F169W, 
and G170A mutants are different from those of wild-type 7 
(Fig. 2). The significant change in serine 
phosphotransferase activity with free Mn^* prompts us to 
suggest that these five residues or the side chains of the 
mutants may be close to metal ion binding sites and be 
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participating in the binding of metal ions. We argue that 
the metal ion binding sites are possibly between the DFG 
loop and the KPEN"® loop, which may be similar to 
cAPK. In cAPK ternary complex, Zheng et al. (1993a,b) 
showed that the location of the second metal ion binding 
site is between Asp^ " (equivalent to Asp^ ®® in y) and Asn^ '^  
(equivalent to Asn"^ in y) and is flanked by an a- and y-
phosphate of ATP. 
In ElllK, E154R, N155H, F169W, and G170A mutants, 
mutations have a pronounced effect on serine kinase 
activity and seem to decrease the inhibitory effect of Mn^* 
on serine kinase activity. In contrast, these five mutants 
had a higher tyrosine kinase activity than their relative 
serine kinase activity. The changes in activities in these 
mutants did not parallel each other. The higher tyrosine 
kinase activity supports our hypothesis that two 
conformations exist because of the different metal ions. 
Both D168E and D168N had less than 1% serine and tyrosine 
kinase activity, suggesting that Asp^®® was important for 
both types of phosphorylation in y. The results with the 
D168E and D168N mutants argue that there is one single 
active site. 
The protein kinase subdomain VI contains specific 
residues characteristic of either the serine/threonine or 
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tyrosine kinases (Hanks et al., 1988). In most 
serine/threonine kinases, a Lys-Pro-Glu^®'' (7 numbering) 
sequence is found, whereas the tyrosine kinases contain 
either an Arg-Ala-Ala or Ala-Ala-Arg sequence (Table 1). 
The E154R mutant was constructed because of this sequence 
alignment and has a 2.5-fold greater tyrosine kinase 
activity than the wild-type 7. It is unclear why this 
point mutation causes such dramatic change in the tyrosine 
kinase activity. Mutagenesis seems to alter the 
conformation around the metal ion binding sites and 
facilitate changes to favor tyrosine kinase substrates 
after the binding of the metal ion. The results suggest 
further that the configurations at the active site region 
between serine/threonine and tyrosine kinases are 
different. 
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ABSTRACT 
Using site-directed mutagenesis, we have proposed that 
an autoinhibitory domain(s) is located at the C-terminus 
region (Taoi-ass) of phosphorylase kinase (PhK) 7-subunit 
(Huang et al. Mol. Cell. Biochem. 1993, 127/128, 7-18). 
Removal of the putative inhibitory domain(s) by truncation 
results in the generation of a constitutively active and 
calmodulin-independent form, Ti-aoo- To probe the structural 
basis of the autoinhibition of 7-subunit activity, two 
synthetic peptides, PhK 13 (7302-326) and PhK 5 (7342-366) , 
corresponding to the two calmodulin-binding regions, were 
used as inhibitors. Inhibition of 71.300 by PhK 13 and PhK 5 
showed that (1) PhK 13 was a more potent inhibitor than PhK 
5; (2) Ca^'"-calmodul in can release the inhibition caused by 
both peptides; (3) PhK 13 showed competitive inhibition 
versus phosphorylase b (K^g = 1.8 /zM) and noncompetitive 
inhibition versus ATP; (4) PhK 5 showed noncompetitive 
inhibition with respect to phosphorylase b {K^g = 62.2 /xM) 
and ATP. These results indicate that there are two 
autoinhibitory domains within the C-terminus of the 7-
subunit and that these two domains overlap with the 
calmodulin-binding regions. Two truncated mutant forms of 
Ti-300 / ElllK, and E154R, were used to probe the enzyme-
substrate binding region using peptide substrate analogs 
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corresponding to residues 9-18 of phosphorylase b 
(KRK^^Q^ISVRGL) . Analyses of kinetic data obtained using 
various combinations of these peptide substrate analogs and 
7-subunit mutants suggest that interacts with the P-3 
position of the substrate (Lys^^) and interacts with the 
P-2 site (Gln^^) . Both ElllK and E154R were competitively 
inhibited with respect to phosphorylase b by PhK 13, with 
14- and 8-fold higher values, respectively, than that 
observed with the wild-type enzyme. These data are 
consistent with the region of the 7-subunit corresponding 
to PhK 13 being a pseudosubstrate-like autoinhibitory 
domain. 
INTRODUCTION 
Phosphorylase kinase (PhK) catalyzes the 
phosphorylation and activation of glycogen phosphorylase b 
(for review see 1, 2). PhK has a subunit composition in 
white skeletal muscle of (a,/3,7, Ô) 4. The at- and /3-subunits 
are regulatory subunits. Their phosphorylations by the 
cAMP-dependent protein kinase (cAPK) or autophosphorylation 
result in enhanced catalytic activity. The 7-subunit is 
catalytically active, and its N-terminal region shares 
sequence homology with the catalytic domains of other 
protein kinases (3, 4). The ô-subunit is calmodulin and 
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confers Ca^* sensitivity upon the enzyme. The C-terminal 
region of 7287-386 is thought to encompass two distinct, non­
contiguous high affinity calmodulin-binding subdomains (5). 
Exogenous calmodulin is known to stimulate the y-subunit 
isolated from rabbit skeletal muscle (6, 7) and recombinant 
full-length y forms (8-12). Yet, the relation between 
calmodulin binding and reactivation is unclear. 
Truncated forms of the 7-subunit obtained using 
proteolysis and site-directed mutagenesis have been used to 
study the structural basis of 7-subunit regulation. A 
catalytic fragment, 7i.29b/ without the C-terminus calmodulin 
binding regions, exhibited greater specific activity than 
either the intact 7-subunit or the 7-calmodulin complex 
(15, 16). In addition, a hypothetical pseudosubstrate site 
(7332-353) has been suggested by Kemp and Pearson (14) . To 
examine the possible existence of autoinhibitory domain(s) 
which might be located outside the catalytic core of the 7-
subunit, seven truncated forms of the 7-subunit have been 
generated by using deletion mutations and their kinetic 
properties studied (12). One of the truncated recombinant 
7 forms, 71-300/ had a 2- and 4-fold greater catalytic 
efficiency {V^/K„) than either the recombinant full-length 
7 (7i-38g) or a longer truncated form of 7 (71.331) (12). This 
evidence suggested that there maybe at least one inhibitory 
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domain in the C-terminal region of y between residues 301-
331. 
Several calmodulin-dependent protein kinases, e.g., 
myosin light chain kinase and calmodulin-dependent protein 
kinase II, have been shown to contain an autoinhibitory 
domain or a pseudosubstrate sequence in their primary 
structures, which partially overlap with their respective 
calmodulin-binding regions (reviewed in 14, 17). In both 
cases, calmodulin plays an important role in releasing the 
inhibition imposed by the inhibitory domain. A series of 
calmodul in-binding peptides, including PhK 13 (7302-326) and 
PhK 5 (7342-366) which correspond to two calmodulin binding 
regions in the C-terminus of 7, were shown to inhibit 
activated PhK (18, 19). The authors suggested that the 
inhibition of PhK activity was because of the binding of 
the calmodulin peptides to calmodulin (ô-subunit) which in 
turn influenced the interactions between the 7-subunit and 
a- and/or /3-subunits (18) . However, the inhibition of PhK 
by melittin, a model calmodulin-binding peptide, suggested 
a direct interaction between the 7-subunit and melittin 
(19). A direct regulatory model of the PhK active site 
being the "calmodulin-like-binding site" is proposed (20). 
Because of these differences between these two studies (18, 
19), the effects of two 7-subunit calmodulin-binding 
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peptides (PhK 13 and PhK 5) on the activity of the 
truncated, constitutively active form of the y-subunit, Yi. 
300 , were evaluated in the current study. This would be the 
simplest method to distinguish between those two hypotheses 
as suggested by Newsholme et al. (18) and Paudel et al. 
(19) because no other regulatory subunit s (a, 13, and Ô) are 
involved in Yi.aoo- In addition, to gain further insight 
regarding the inhibition mechanism, we first mapped 
substrate binding sites between Y1.300 and peptide substrate 
(described below) and then utilized this information to 
further confirm the inhibition mechanism of PhK 13. 
K'RKQISVRGL^®, a peptide with the amino acid sequence 
of the phosphorylatable region of phosphorylase b, has been 
used as an alternative substrate of PhK (20) and the 7-
subunit (6, 12, 21). This peptide (9-18 peptide) contains 
the phosphorylatable Ser" of phosphorylase b, which will 
be referred to as P site in this paper. It has been 
suggested by Graves and his colleagues (22) that not all 10 
amino acid residues of 9-18 peptide are important for PhK 
recognition. Several residues, including Lys"^ (the P-3 
site) and Arg^ (the P+2 site), are crucial for optimal 
phosphorylation. However, Gin" (P-2 site) is also 
suggested to be important for phosphorylation (22). The 
interactions between the enzymes and their substrates can 
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be identified by analyzing the crystal structures of the 
enzymes bound to their substrates. No crystal structure is 
available for the 7 but molecular modeling suggests that 
its structure has considerable similarity to that of cAPK. 
Based on the data of crystal structure of cAPK-inhibitor 
complex (23, 24) and mutagenesis studies of yeast cAPK (25, 
26) , it has been concluded that Glu^^'' and Glu^'" in cAPK 
(equivalent to Glu"^ and Glu"^ in 7) are involved in the 
recognition of both Args in P-3 and P-2 of Kemptide (LRP'^RP" 
A^SLG) . It has been shown that two mutant forms of 71.300/ 
ElllK and E154R, are important for substrates binding 
(approximately 6- and 3-fold increases in values for 
phosphorylase b and ATP, respectively (27)) . It wasn't 
clear whether Glu^^^ and Glu^®" in 71.300 were involved in 
peptide substrate binding similar to that of cAPK with 
Kemptide. In this study, we utilized charge reversal 
peptide analogs and mutants forms of 71.300 to identify the 
interactions between Glu residues (Glu^ ^^  and Glu^ ") in 71.300 
and Lys^^ (P-3 site) and Gin" (P-2 site) in 9-18 peptide 
substrate. Based on these substrate binding sites mapping 
results and studies with the peptides, PhK 13 and PhK 5, we 
suggest the inhibition mechanism of PhK 13 is via 
pseudosubstrate mechanism. Binding of PhK 5 to 71.300 is 
through the inhibitory mechanism. 
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MATERIALS AND METHODS 
Materials-[7-^^P] ATP was purchased from ICN 
Biomedicals. Other reagents were purchased from Sigma. 
Phosphorylase b was prepared from rabbit skeletal muscle as 
described in (28), and residual AMP was removed by 
treatment with acid-washed Norit. PhK 13 
(GKFKVICLTVLASVRIYYQYRRVKP), 9-18 peptide (KRKQISVRGL), 
corresponding to the amino terminal residues 9-18 of 
phosphorylase b, and its analogs were synthesized at the 
Iowa State University protein facility and purified by 
reverse-phase HPLC C-18 column. PhK 5 
(LRRLIDAYAFRIYGHWVKKGQQQNR) was synthesized at the 
University of Utah and purified as described previously 
(5) . 
Expression and purification of mutant y-subunits-
Expression of 71.300 and its mutant forms, ElllK and E154R, 
were done by using the T7 RNA polymerase-based expression 
system (29) as previously described (12). All of the 
recombinant proteins were purified to homogeneity as judged 
by SDS gel electrophoresis (data not shown). 
Protein concentration determination-Protein 
concentrations were determined by the Bradford assay with 
commercially prepared reagents from Bio-Rad (30). 
Activity assay-The protein kinase activity of the 7-
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subunit was determined by incorporation of into 
phosphorylase b as previously described with some 
modification (6, 31). The standard assay contained the 
final concentrations of 50 mM Tris, 50 mM HEPES, pH 8.2, 10 
mM MgClj, 100 /iM phosphorylase jb, 1 mM DTT, 1 mM [y-^^P] -
ATP, 0.1-2 /iM Yi.300 (wild-type and mutant forms). In the 
inhibition assays, the standard assay was performed except 
that PhK 13 or PhK 5 were added and the final concentration 
of phosphorylase b was adjusted to 4 //M. After incubated 
at 30°C for 5 min, equal amounts of calmodulin (or BSA) 
were added and incubated for another 5 min at 30°C. The 
reaction mixture was spotted on ET-31 filter paper 
(Whatman), washed with TCA, and the radioactivity 
incorporated was determined by liquid scintillation 
counting (32) . Kinetic data were analyzed with the 
program, Enzfitter (Elsevier Science Publishers). The 
initial velocity data were fitted to the equation for a two 
substrate random bi bi mechanism. The inhibition data with 
PhK 13 and PhK 5 were fitted to the equations for 
competitive or noncompetitive inhibition (described in 
results). 
In the kinetic analyses, the range of substrate 
concentrations for all experiments was varied from 1/2 K^ 
to 5 times K^  for each enzyme. With wild-type 71.300/ 
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studies were done using (a) varying concentrations of 
phosphorylase b (10-90 /liM) and inhibitor peptides (0-7.2 /xM 
for PhK 13 and 0-51 /xM for PhK 5) and a fixed concentration 
of ATP (400 ixM) ; (b) varying concentrations of ATP (40-400 
liM) and inhibitor peptides (0-54 /xM for PhK 13 and 0-51 /xM 
for PhK 5) and fixing the concentration of phosphorylase b 
(90 iM) . However, the K^, values for phosphorylase b using 
the ElllK and E154R mutants were both around 100 /xM. It 
was impossible to obtain a final concentration of 500 fxM 
phosphorylase b (5 times K^) in the assay due to the 
limited solubility of phosphorylase b. A concentration of 
225 /xM of phosphorylase Jb was used as the highest 
concentration in the assay. Similar experimental 
conditions were applied to the mutant forms of 71.300-
RESULTS 
Effects of PhK 13 and PhK 5 on 7i.joo-To determine 
whether the 7-subunit calmodulin-binding subdomain 
peptides, PhK 13 and PhK 5 could act as possible 
autoinhibitory domain(s), these peptides were tested for 
their ability to inhibit the constitutively active 7, 71.300-
The results showed that both peptides could inhibit the 
kinase activity of 71.300- PhK 13 showed a more potent 
inhibitory effect than PhK 5 (Fig. 1). The reversal of the 
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inhibition by calmodulin is shown in Fig. 2. Because Y1.300 
has no calmodulin binding sites, it is not surprising that 
there is a lack of Ca^Ycalmodulin activation on 71.300 but 
the inhibition of Y1.300 by PhK 13 and PhK 5 can be reversed 
by calmodulin. Inclusion of Ca^* with calmodulin did not 
change the response with this concentration of calmodulin. 
Another protein, BSA, had little or no effect on the 
inhibitory effects of PhK 13. 
Kinetic analyses of the inhibition of Ji.300 Jby PhK 13 
and PhK 5-Kinetic analyses were undertaken to determine the 
mechanism of the inhibitory properties of PhK 13 and PhK 5 
on 71-300 • The results of these analyses showed that PhK 13 
is a competitive inhibitor of phosphorylase b 
phosphorylation with K^g=l. 8 /xM and a noncompetitive 
inhibitor of ATP (Kjs=30.9 /iM and Kjj=29.8 /xM) (Table 1 and 
Fig. 3). In contrast, PhK 5 is a noncompetitive inhibitor 
of phosphorylase b (K^s=62.2 fzM and K^_(=63.1 (JLM) and ATP 
(Kis=119 /iM and K^_(=116 /xM) (Table 1 and Fig. 3) . No 
further attempt was made to locate the possible binding 
site of PhK 5 in 71.300 because noncompetitive inhibition 
with respect to both substrates indicates PhK 5 may be 
binding at a site other than the ATP and phosphorylase b 
binding sites. 
Mapping the Substrate Binding Sites Using Peptide 
Figure 1. Comparison of the inhibition of Yi-soo by PhK 13 and PhK 5. The assay 
conditions were described in Materials and Methods. 
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Figure 2. Inhibition of 71.300 activity by PhK 13 or PhK 5. Activity was assayed as 
described under "Materials and Methods". The final concentrations of PhK 
13 or PhK 5 were 10 /xM and 250 /xM, respectively. Equal amounts of 
calmodulin (with 0.1 mM CaClz or 1 mM EGTA) or BSA were used in the 
reaction mixture. 
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Table 1. Kj values and kinetic mechanisms for the inhibition of 71.300 and its 
mutant forms. 
Varied 
y forms Inhibitors Substrates Inhibition K_,-/ 
Wild-Type PhK 13 Phos. b Competitive 1.8 ± 0 .1 -
Wild-Type PhK 13 ATP Noncompetitive 30.9 ± 1 .5 29.8 ± 1 .3 
Wild-Type PhK 5 Phos. b Noncompetitive 62.2 + 3 .0 63.1 ± 3 .5 
Wild-Type PhK 5 ATP Noncompetitive 119 ± 4 116 + 3 
ElllK PhK 5 Phos. b Noncompetitive 67.2 ± 2 .1 67.7 ± 2 .2 
E154R PhK 5 Phos. b Noncompetitive 101 ± 6 106 + 4 
ElllK PhK 13 Phos. b Competitive 25.8 + 1 .3 -
ElllK PhK 13 ATP Noncompetitive 91.9 ± 4 .6 90.0 ± 4 .5 
E154R PhK 13 Phos. b Competitive 15.0 ± 1 .2 -
E154R PhK 13 ATP Noncompetitive 69.7 ± 5 .1 H
 
00
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"Equation 1 gives the rate expression for competitive inhibition. 
Kj. = (E) (I)/(EI) . 
11 Ka Ka 
= + + [ ] (I) (1) 
V (A) Kj. (A) 
"Equation 2 represents the rate expression for noncompetitive inhibition. 
Kj. = (E)(1)/(EI); Kjj = (EA) (I)/(EAI) . 
1 1 (I) Kj. (I) 1 
= [ 1 + ] + [ 1 + ] ( ) (2) 
V K,, Kj. A 
Figure 3. Initial velocity patterns for inhibition of Y1.300 
by PhK 13 (A) and PhK 5 (B). Activity was 
assayed as described under "Materials and 
Methods". The concentrations of PhK 13 and PhK 5 
were indicated. 
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Analogs-Previously, Graves and coworkers demonstrated that 
Lys^^ (P-3 site) of the 9-18 peptide was the most important 
basic residue on the N-terminus of Ser" (P site) for PhK 
recognition (22) . To test whether 71.300 has the same 
specificity determinant as PhK, three 9-18 peptide analogs 
were prepared by replacing Lys®, Arg^°, and Lys^^, with 
glutamyl. These peptide analogs were termed E9, ElO, and 
Ell, respectively (Table 2). Peptide 9-18 and its 
glutamyl-substituted peptides were individually tested as 
substrates of Y1.300 to evaluate the effects of charge-
reversal on substrate recognition by 71.300- Table 2 lists 
the results of these kinetic analyses and relative 
enzymatic efficiency (pepude/ (K,ax/-Km) 9-18 peptide• 
Peptide ElO showed little change in relative enzymatic 
efficiency (120%) , whereas E9 showed a modest decrease 
(40%). These data indicated neither Lys* and Arg^° in 
peptide 9-18 essential for 71.300 recognition. A greater 
effect was seen when Ell was used as a substrate for 71.300-
The relative efficiency (10%) shows that Ell (Lys^^ -> Glu) 
was a poor substrate compared to 9-18 peptide. Because of 
the large effect on the value (a 10-fold difference), we 
suggest that Lys^^ at the P-3 site in 9-18 peptide is 
important for substrate recognition. 
To determine which residues in 71.300 participate in the 
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Table 2. Comparison of kinetic parameters of Y1.300 using 
various peptide substrate analogs. 
"Peptides K„ 
(mM) 
9-18 0.9 ± 0.1 
E9 1.94 ± 0.02 
ElO 0.87 ± 0.07 
Ell 9.0 ± 0.6 
V„ax "Relative 
(nmol/min/nmol) Efficiency 
1400 ± 300 1.0 
1310 ± 20 0.4 
1620 ± 150 1.2 
1480 ± 200 0.1 
* 9-18 : K®-R-K-Q-I-S-V-R-G-L" 
E9 : E -R-K-Q-I-S-V-R-G-L 
El0 : K -E-K~Q~I~S~V-R-G~IJ 
Ell ; K -R-E-Q-I-S-V-R-G-L 
® Relative efficiency was calculated as 
peptide/ 9-10 
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binding of Lys" at P-3 site in 9-18 peptide, two charge-
reversal mutants of Yi-soo' ElllK and E154R, were examined. 
Both of these mutants were shown earlier to influence 
substrate binding (27) . Wild-type Y1.300 and both ^1-300 
charge-reversal mutants were subjected to kinetic analyses 
using 9-18 and Ell peptides as substrates. If either 
residue or E^®^ in Y1.300 interact with the residue at the 
P-3 site of 9-18 peptide, it would be expected that charge 
reversal mutations at these positions would negatively 
affect substrate kinetics and that charge reversal at the 
P-3 site in the peptide, Ell (Lys" -> E), would reverse or 
attenuate these effects. The kinetic data and relative 
efficiencies from these experiments are presented in Table 
3. As mentioned earlier, in wild-type Yi-soo a 10-fold 
higher value was observed using Ell as a substrate than 
with 9-18 peptide. There were no significant differences 
in the or values of the E154R mutant using either 
Ell or 9-18 peptide. These data suggest that Glu^ " in 71.300 
does not interact with the P-3 residue in the substrate. A 
very dramatic increase in the relative efficiency of ElllK 
mutant toward Ell peptide (36-fold) was found. The higher 
relative efficiency of ElllK toward Ell peptide was 
reflected by a 3-fold decrease in K^, and a 10-fold increase 
in Vmax- The results indicate that the charge reversal in 
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Table 3. Efficiency of 9-18 and Ell peptides as substrates 
of wild-type 71.300 and its charge-reversal mutant 
forms, ElllK and E154R. 
Enzyme Substrate ®Relative 
(mM) (nmol/min/nmol) Efficiency 
Wild-type 9-18 0 .9 ± 0.1 1400 ± 300 1 .0 
Ell 9 . 0 ± 0.6 1480 ± 200 0 .11 
E154R 9-18 4 .1 ± 0
 
W
 690 ± 150 0 .11 
Ell 4 .1 ± 0.3 470 ± 80 0 .074 
ElllK VO 1 H CD
 
5 . 0 ± 0.5 10 ± 1 0 . 0013 
Ell 1. 52 ± 0.02 109 ± 3 0 .046 
® Relative efficiency was calculated as Table 2. 
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TI-3OO -> K) was compensated by the peptide substrate 
charge reversal (Lys^^ -> Glu). We interpret these data to 
mean that Glu^^^ in Yi-aoo interacts with the P-3 site of the 
9-18 peptide substrate. 
To learn whether (equivalent to in mammalian 
cAPK) interacts with the P-2 site in the substrate as in 
the case of cAPK, the kinetics of phosphorylation of two 
synthetic peptides substituted at the P-2 site, SI 
(R^^KQISVR^®) and S2 (R^°KEISVR) , were analyzed. Charge 
reversal at residue 154 in Yi-aoo -> R) and substitution 
at the P-2 residue in the substrate peptide (Q" -> E) 
would be predicted to improve substrate kinetics if there 
are interactions between residue 154 and the P-2 site in 
the substrate. The data confirmed the prediction, show a 
higher relative enzymatic efficiency with E154R toward S2 
peptide (0.082) than wild-type peptide (0.010) (Table 4). 
The results support the view that E^®"* interacts with the P-
2 site in the 10-18 peptide (SI). 
Pseudosubstrate or inhibitory mechanism-To provide 
additional evidence that PhK 13 might act to inhibit 71.300 
via a pseudosubstrate mechanism, PhK 13 inhibition was 
assayed with both the ElllK and E154R mutants of 71.300- It 
is predicted, based on the sequence alignment of PhK 13 and 
phosphorylase h, that mutation of Glu^^^ to a lysyl residue 
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Table 4. Efficiency of SI and S2 peptides as substrates of 
wild-type Y1.300 and its mutant form, E154R. 
Enzyme "Peptide ®Relative 
(mM) (nmol/min/nmol) Efficiency 
Wild-Type SI 3 . 9 ± 0.5 142 ± 10 1.0 
S2 7.6 ± 0
 
00
 
237 ± 16 0.86 
E154R SI 21 ± 1 7.7 ± 0.3 0.010 
S2 4 ± 1 12 ± 2 0 , 082 
* SI : R"-K-Q-I-S-V-R" 
S2 : R"-K-E-I-S-V-R" 
® Relative Efficiency was calculated as si or 
Sz/ (^max/^m) si • 
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will lower the affinity of the enzyme for PhK 13 due to 
charge repulsion with the P-3 site of PhK 13. Thus 
if the binding of PhK 13 to the enzyme occurs with a 
pseudosubstrate orientation, a higher K^g value would be 
expected. 
Both ElllK and E154R mutants were assayed using fixed 
concentrations of ATP and variable concentrations of 
phosphorylase b and PhK 13. Both ElllK and E154R were 
inhibited competitively by PhK 13 with respect to 
phosphorylase b and the K^, values of PhK 13 towards ElllK 
and E154R were increased 14- and 8-fold, respectively, 
compared to wild-type 71.300 (Table 1) . It is, however, 
unclear whether the weaker inhibition by PhK 13 was caused 
by the properties of both ElllK and E154R mutants. Similar 
experiments were performed using ATP and PhK 13 as the 
variable substrate and inhibitor, respectively, and 
constant phosphorylase b. Noncompetitive inhibitions with 
respect to ATP with 3- and 2-fold increases in K^g values 
were found in ElllK and E154R mutants, respectively (Table 
1) . 
Because PhK 5 is a noncompetitive inhibitor, we also 
analyzed the inhibition of both mutants by PhK 5 to ensure 
that PhK 13 specifically competed with phosphorylase b at 
its binding site. The analyses revealed that the K^g value 
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of PhK 5 towards phosphorylase b with either mutant was 
identical to that of wild-type ^1-300 (Table 1) . These data 
suggest that neither Glu"^ nor Glu"'' are involved in 
binding PhK 5. 
Identification of a pseudosubstrate seguence-Because 
the above data suggested that PhK 13 interact with the 
phosphorylase b binding site and because inspection of the 
PhK 13 sequence reveals that there is a possible region 
which could mimic the substrate recognition motif (Table 
5), we evaluated whether PhK 13 could serve as a substrate 
for 71-300 • Table 5 shows the sequence alignment of 
phosphorylase b (between residues 9 and 18) and PhK 13 
(309-318). Based on the sequence alignment, PhK 13 is very 
likely to be a substrate of 71.300 because of in the P+2 
position which is an important substrate specificity 
determinant for PhK. The result showed that PhK 13 was a 
substrate for 71.300 with K^ value of 0.9 mM, which was 
similar to that for the 9-18 peptide as a substrate. The 
value was only 1/20 of that for the 9-18 peptide. 
DISCUSSION 
Studies of charged-to-alanine mutants and alanine-
substituted Kemptide analogs, Gibbs and Zoller (25) have 
identified three glutamic residues in yeast cAPK 
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Table 5. (A) Sequence alignments of the possible 
pseudosubstrate regions; (B) Comparison of 
peptides recognition sites in 71.300 and in cAPK 
(A) Phos. b (9-18) K-R-K-Q-I-S-V-R-G-L" 
PhK 13/7(309-318) L-T-V-L-A-S-V-R-I-Y^" 
(B) 
7 Residues gl54 y 1^ 222 
Peptide Substrate KRKQISVRGL 
Phos. Jb (9-18) 
Inhibitor Peptide KFKVICLTVL 
PhK 13 7(303-312) 
Kemptide 
cAPK Residues 
(mammalian cAPK) 
L R R A S L G 
E170/E230 
E127 
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(equivalent to E"', and in the mammalian cAPK) 
that are involved in recognition of the peptide substrate 
Kemptide. E"'' contributes to the recognition of the P-3 
Arg and E^''° and E^^° interact with the Arg at P-2 position. 
Their results are in agreement with the data from the 
crystal structure of a peptide inhibitor bound to the cAPK 
(23, 24). Using similar approach, but with charge-reversal 
instead of charge-to-alanine in both enzyme and peptide 
substrate, the substrate binding sites of Y1.300 were mapped. 
Two major conclusions reached are that (a) substrate 
specificity determinants for PhK and 71.300 are very likely 
the same; (b) E^^^ and E"^ (equivalent to E""' and E"° in the 
mammalian cAPK) are involved in the recognition of the P-3 
and P-2 sites of 9-18 peptide. 
The residues corresponding to E"' and E^""" in cAPK are 
conserved in the 7-subunit as E^^^ and E^®^. However, E^^°, 
which interacts with the P-2 Arg, in cAPK is replaced by 
in the 7-subunits (Table 5). If the same alignment 
exists in the two proteins at P-2 site, this suggests the 
H-bonding occurs between the 7-subunit and Gin" at the P-2 
site in phosphorylase. Also, unlike cAPK, Arg^ at P+2 
site was shown early as an important substrate specificity 
determinant (22). The basic residues on both sides of 
Ser" seem to be required for substrate recognition for PhK 
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but the second basic residue at P+2 is inhibitory for cAPK. 
Even though both and E^®" contribute to the same 
substrate binding positions as cAPK does, we believe that 
the binding between both positions (E^^^ and E^®"*) in the 7-
subunit and phosphorylase b is not the same as cAPK with 
kemptide. 
The use of the calmodulin-binding peptides have 
provided several views about the activation mechanism of 
PhK (18, 19). All of these studies were done using PhK 
holoenzyme. We, in contrast, used a constitutively active 
truncated form of the 7-subunit, 71.300/ which is the 
simplest form of PhK, to directly evaluate one of the 
possible mechanisms of PhK regulation. This truncated 
recombinant 71.300 form has several advantages over PhK 
holoenzyme: (a) both PhK and the 7-subunit have the same 
active site and substrate specificities; (b) the 2-fold 
higher specific activity of 71.300 than PhK holoenzyme 
indicates the release of inhibition by a/fi subunits and 
other factors, e.g. pH, and autophosphorylation; (c) site-
directed mutagenesis can be applied in the studies to help 
us reveal the precise inhibitory mechanism. 
The PhK 13 sequence Lys^''®-Val^°®-Ile^°''-Cys^°® is similar 
to that of the N-terminal region of the 9-18 peptide (see 
Table 5) and has been suggested by Dasgupta and Blumenthal 
147 
(33) to be il likely pseudosubstrate sequence. The sequence 
is characterized by a basic residue (Lys^°®) , two 
hydrophobic residues, and alignment of Cys^°® of PhK 13 with 
Ser" of phosphory1ase b. In this study, we concluded that 
ElllK and E154R interacted with the P-3 and P-2 sites of 9-
18 peptide, respectively, and that PhK 13 is a competitive 
inhibitor with respect to phosphorylase Jb, indicating that 
PhK 13 bound to the substrate binding site. But, it is 
important to note that peptide could bind anywhere in the 
enzyme. To confirm Phk 13 is really bound to the substrate 
binding site, we further characterized its inhibitory 
effects by applying both ElllK and E154R mutant enzymes in 
this study. Based on the kinetic analyses of PhK 13 on 
ElllK and E154R (competitive inhibition against 
phosphorylase b with higher K^g values) and PhK 5 on both 
mutants (noncompetitive inhibition against phosphorylase b 
with no change in the K^g values), we suggest that a basic 
residue at the P-3 site causes the repulsion with ElllK. A 
hydrophobic residue (V^°®) at the P-2 site of PhK 13 
decreases the binding of E154R mutant as illustrated by the 
higher K^g value. The evidence suggest that residues N-
terminal to (in PhK 13) and to S" (in 9-18 peptide) 
might bind to the active site of Yi.joo similarly. 
The regulation of PhK activity is very complicated. 
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In this study, we suggest an activation mechanism of PhK. 
Our results are consistent with a model in which the 
activity of the 7-subunit of PhK is regulated by the 
pseudosubstrate binding domain located on the C-terminus of 
7302-326 and the inhibitory domain located on 7342-366 • Because 
the same region bind calmodulin it is likely that the 
autoinhibitory action of this region is regulated by 
calmodulin (the ô-subunit). But in our experiments no 
calcium was needed for good activation. This could be due 
to the fact that tight binding of calmodulin to the 7-
subunit can occur in the absence of calcium. At this 
point, the physiological significance of this activation 
mechanism seen in vitro is not established. Our assignment 
of the pseudosubstrate sequence supports that inhibition of 
7I-3OO by PhK 13 is mediated by residues Lys^°®, Val^"®, and 
Cys^os 0 and directly participates in the binding of the 
active site of 71.300 as suggested by Paudel et al. (19). 
Some experimental results concerning the inhibition 
mechanism of PhK holoenzyme by PhK 13 and PhK 5 are 
contradictory. For example, one laboratory reported that 
both PhK 13 and Phk 5 had noncompetitive inhibition 
mechanisms with respect to phosphorylase b but no plots 
were shown (18). In contrast, another laboratory suggested 
from kinetic studies that both PhK 13 and PhK 5 were 
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competitive inhibitors with respect to phosphorylase b 
(33). The reason for these discrepancies is not clear. 
These differences may reflect the differences in the assay 
procedures used because ionic strength and pH are known to 
affect the activity of PhK (1). These conditions might 
influence the interactions between regulatory subunits and 
7 subunit in the holoenzyme. 
The evidence presented in this paper raises more 
questions concerning the regulation of PhK. Still 
unanswered is why there are multiple calmodulin binding 
peptides (derived from PhK or other sequences, e.g. 
melittin) which have the ability to inhibit the activity of 
PhK and/or 71.300* In addition, several calmodulin-binding 
proteins, e.g. myosin light chain kinase and calcineurin, 
also bind to melittin. The results seem to imply the 
active site of PhK (or the 7-subunit) has the structural 
resemble to the calmodulin, which binds to those calmodulin 
binding peptides. A similar idea was proposed by Paudel et 
al. (19) in studying the melittin and PhK. 
So far, there are at least two peptides (34) 
and PhK 13) derived from PhK which show competitive 
inhibition towards phosphorylase Jb. However, there is only 
one active site in PhK (or the 7-subunit). This raises 
another question about which sequence is a real 
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pseudosubstrate sequence regulating PhK (or the y-subunit) 
activity. Although PhK 13 is a more potent inhibitor than 
)342o-436 / we are still unable to address this question 
without any evidence showing the direct interaction between 
subunit and subunit. The in vivo protein-protein 
interaction system (two hybrid system) is currently being 
applied in our laboratory to probe the interactions between 
subunits (35) . Until then, we cannot conclude either 
436 or PhK 13 is responsible for regulating the PhK 
activity. 
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CHAPTER 5 
GENERAL SUMMARY AND DISCUSSION 
The overall aim of my work was to contribute new 
information which will help us and others understand the 
molecular basis of substrate specificity and regulatory 
properties of the PhK catalytic subunit. 
I have expressed PhK 7 subunit (full-length and 
truncated mutant forms of 7) in E. coll. Because the 
recombinant PhK 7 expressed at a high level is in the 
inclusion bodies (35) . I need to develop a process to 
isolate, solubilize, renature, and further purify 
recombinant protein. Two of the truncated forms of 7, 71.300 
and 71-290/ were purified to homogeneity and showed 2-3 fold 
higher specific activity than that of the full-length 7, 
7i-386 - Several properties of the full-length 7 and the 
truncated 7 form, 71.300/ were determined and compared with 
the PhK isolated from rabbit skeletal muscle. Both of 
these enzymes showed similar substrate specificity, metal 
ion requirements, and pH dependency (34, 35). However, the 
truncated 71.300 has several advantages over full-length 7: 
(a) it has similar K^ values for phosphorylase b and ATP as 
the full-length 7 but has a higher k^a^; and (b) it has 
higher purity than full-length 7 and can be recovered from 
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the inclusion bodies with good yields. Therefore, this 
truncated Y1.300 form was used to explore regulation, dual 
specificity, and metal ion binding sites of the catalytic 
subunit. 
An important question not answered is what features in 
phosphorylase b and PhK are crucial for recognition. To 
answer this question, the crystal structures of the enzyme 
bound to its substrate are required. No crystal structure 
is available for 7, but molecular modeling of 71.300 suggests 
that its structure has considerable similarity to that of 
the crystal structure of cAPK (Cox et al., manuscript in 
preparation). Based on the data of crystal structure of 
cAPK-inhibitor complex (53, 54), systematic mutageneses of 
Ti-300 were used to identify the acidic residues in the 
recombinant enzyme involved in recognition of basic 
residues and R^®) in the peptide substrate. These two 
positive charged residues are important substrate 
specificity determinants for PhK and 7. 
Two mutant forms of 71.300/ ElllK and E154R, and wild-
type 7I.3OO were used to probe the enzyme-substrate binding 
region using 9-18 peptide and its analogs. The results 
suggest that interacts with P-3 site (K^^) of 
phosphorylase b and binds to P-2 position (Q") , which 
is also an important substrate specificity determinant for 
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TI-3OO (51, 52) . However, in this study, the attempt to 
locate the acidic residue(s) which interacts with in 
phosphorylase b were not successful because not all acidic 
residues in 71.300 were mutated as mentioned earlier in the 
GENERAL INTRODUCTION. Inspection of the y subunit sequence 
reveals that it contains a SAE®^E®^VQE®® sequence and the 
acidic residues may be important for recognition of the P+2 
R^® (Cox et al., manuscript in preparation). In 
conclusion, knowledge about enzyme and substrate binding 
sites will certainly help us better understand the 
structural aspects of how PhK recognizes phosphorylase b, 
why PhK and cAPK display several differences on substrate 
specificity, and how the enzyme is regulated. 
Removal of the catalytic subunit's C-terminal domains 
by proteolytic digestion of PhK or deletion mutations of y 
gives rise to its activation, suggesting the existence of 
an autoinhibitory domain in the C-terminus of y (35, 63-
65). To probe the structural requirement of the inhibition 
of y activity, two synthetic peptides, PhK 13 and PhK 5, 
corresponding to the two calmodulin binding regions, were 
used as inhibitors. Based on substrate binding sites 
mapping results and studies with inhibitor peptides (PhK 13 
and PhK 5) and recombinant Y1.300 proteins (wild-type, ElllK, 
and E154R) , we suggest that inhibition of 71.300 is because 
157 
of the presence of one pseudosubstrate (7302-326 PhK 13) 
and one inhibitory (7342-366 or PhK 5) sequences in the C-
terminus of 7. These two sequences overlap with the 
putative calmodulin-binding sites of 7. In the absence of 
calmodulin, the pseudosubstrate domain binds to the active 
site and inhibits the catalytic activity of 7. Activation 
occurs by calmodulin which binds the inhibitory segments 
and removes them from the active site of 7. 
Several putative calmodulin-binding peptides (derived 
from PhK or other sequence, e.g. melittin) possess the 
ability to inhibit the kinase activity of PhK (41, 43) 
and/or 71.300- In addition, several calmodulin-binding 
proteins, e.g. myosin light chain kinase and calcineurin, 
also bind to melittin (40). All of these information raise 
the question why calmodulin-binding peptides can inhibit 
the kinase activity of PhK and 71.300. The most probably 
explanation for this would be PhK and 71.300 possess a 
calmodulin-like active site region. It would be difficult 
to provide any direct evidence to prove this hypothesis 
except to cocrystalize the 71.300 and calmodul in-binding 
peptide. 
PhK recently has been shown to be a dual specificity 
kinase (10). The specificity of PhK is dependent on the 
metal ions; Mg^* activates seryl phosphorylation of 
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phosphorylase b and Mn^* causes tyrosyl phosphorylation of 
angiotensin II. One active site but two different 
conformations with the presence of different metal ions was 
proposed. Using mutant proteins (ElllK, E154R, N155H, 
F169W, G170A), we have suggested that the metal ion binding 
sites of y reside between the D^®®FG loop and the 
KPE^"N loop similar to the metal ion binding sites in cAPK. 
These mutant proteins seemed to have lower serine kinase 
activity and lessen the inhibitory effect of Mn^* on serine 
kinase activity when compared to wild-type enzyme. On the 
other hand, these five mutants had a relatively higher 
tyrosine kinase activity than their relative serine kinase 
activity. The changes in activities did not parallel each 
other. The higher tyrosine kinase activity supports our 
hypothesis that two conformations exist because of the 
different metal ions. Mutations on the invariant Asp 
residues (D150N, D168E, and D168N), which are thought to be 
involved in catalysis in serine kinase activity, knock out 
both the serine and tyrosine kinase activity of 71.300/ 
suggesting that one active site is involved in both 
activities. These results and other chemical modification 
result (10) support our findings. 
New substrates and pathways might exist for PhK beyond 
the known glycogenolysis cascade because of its dual 
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specificity (Figure 1). To explore such possibilities, I 
have taken several approaches. One of the experiments was 
using 23A2 muscle cells as the substrates. Using 
phosphotyrosine antibody and immunoprecipitation, I have 
identified two proteins, which are phosphorylated on 
tyrosine in muscle cell extracts either directly or 
indirectly by PhK. At this point, the physiological 
significance of this tyrosine phosphorylation seen in vitro 
is not established. However, this experiment certainly 
raises the possibility of the existence of new substrate(s) 
and pathway(s). 
Figure 1. The glycogenolysis cascade and a hypothetical 
pathway for PhK. New substrate(s) and 
pathway(s) might exist for PhK to reflect its 
tyrosine kinase activity. 
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